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ABSTRACT 
 
 
 Tumor cells experience a limiting microenvironment due to inadequate 
vascularization that can affect the normal functioning of intracellular organelles.  In the 
case of the endoplasmic reticulum, the limiting environment is further exacerbated by the 
high metabolic demands of the tumor cells, which together interfere with the proper 
maturation of nascent proteins synthesized there. The resultant accumulation of unfolded 
proteins activates a signal transduction pathway known as the Unfolded Protein 
Response, which serves primarily to protect the cell during stress and helps restore 
homeostasis to this organelle.  As tumors expand resulting in regions that are a greater 
distance from functional blood vessels, they become increasingly hypoxic, which 
ultimately results in the activation of another stress pathway that is primarily regulated by 
the hypoxia inducible factor family of transcription factors (HIFs).  This pathway protects 
cancer cells, in part, by up-regulating VEGFA, which stimulates blood flow to the tumor 
in a process known as angiogenesis.  The interplay between these two stress pathways in 
tumor cell survival is relatively unexplored.  
 
 Microarray analysis of the unfolded protein response in a human medulloblastoma 
cell line revealed that, in addition to known targets, a large number of proangiogenic 
factors were up-regulated.  Real-Time PCR analyses confirmed that four of these factors, 
VEGFA, FGF2, angiogenin and IL8, were transcriptionally up-regulated in multiple cell 
lines by various ER stress inducers.  Our studies on VEGFA regulation revealed that 
ATF4, a UPR-inducible transcription factor, bound to the mouse and human VEGFA 
promoters.  Using a combination of mouse embryonic fibroblasts and human 
neuroblastoma cell lines that are deficient in this transcription factor, we demonstrated 
that ATF4 binds to the VEGFA promoter and contributes significantly to VEGFA 
expression in response to ER stress. We also found that VEGFA mRNA stability is 
increased in response to UPR activation, via activation of AMP kinase, demonstrating 
that increased mRNA levels occur at two regulatory points.  In keeping with the 
increased mRNA levels, we found that VEGFA protein is secreted at levels as high as or 
higher than that achieved in response to hypoxia. Because the inadequate 
microenvironment experienced by solid tumors is expected to activate both UPR and HIF 
signaling pathways, we tested for possible interaction between them. Our studies show 
that VEGFA transcription rate and secreted protein levels are induced to a greater extent 
when both of these pathways are activated together as compared to each stress alone.  
Although we demonstrated a synergy between the two stress pathways experienced by 
tumor cells, surprisingly we found that this was not through the combined effects of the 
two different transcription factors, but instead that UPR activation can enhance HIF 
signaling, which has implications for other HIF targets that aid in tumor survival.  
 
 Our results indicate that the UPR plays a significant role in inducing positive 
regulators of angiogenesis.  In the case of VEGFA expression this occurs at 
transcriptional, post-transcriptional and post-translational levels and is likely to have 
widespread implications for promoting angiogenesis in response to normal physiological 
cues as well as in pathological conditions like cancer.   
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CHAPTER 1.    INTRODUCTION1 
 
 
Angiogenesis 
 
The continued synthesis, sprouting and migration of blood vessels from pre-
existing ones and remodeling of the vasculature is known as angiogenesis [1].  This 
process is required for normal development and homeostasis in a healthy organism.  The 
complex network of tubular structures consisting of blood and lymphatic vessels that 
make up the vascular system are formed primarily by endothelial cells and serve to 
transport oxygen, nutrients, and cell signaling molecules between various tissues and 
organs in vertebrates.  In addition to its role in normal physiology, increased angiogenesis 
contributes to the progression of several pathological conditions including cancer, 
macular degeneration, cardiac and inflammatory diseases [1].  Alternatively, the 
malformation or dysfunction of the vasculature can result in decreased blood supply to 
tissues causing ischemia [2].  Thus, a fine balance between proangiogenic factors that 
promote endothelial cell growth and antiangiogenic factors that limit it must be achieved 
to maintain a normal, functioning vasculature.  Understanding the mechanisms by which 
this balance is maintained during normal physiology or how it is disrupted in disease 
conditions has been the focus of a large number of studies in recent years. [3] 
 
Proangiogenic factors including vascular endothelial growth factor (VEGF), 
fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), and IL8 are 
released by cells experiencing inadequate oxygen and nutrient supplies.  These 
proangiogenic factors act as ligands that bind to specific receptors on endothelial cells 
causing them to release matrix metalloproteinases that degrade the extracellular matrix, 
which allows the endothelial cells to migrate toward the angiogenic stimulus and to 
proliferate in order to establish new blood vessels [4]. The predominant and best-studied 
proangiogenic factor is VEGFA, a homodimeric heparin binding glycoprotein that is 
produced in several isoforms due to alternative splicing (Figure 1-1).  All VEGF isoforms 
are synthesized and processed in the endoplasmic reticulum (ER) and transported through 
the secretory pathway [5].  There are five different splice variants of the human VEGFA 
gene (206, 189, 165, 145 and 121) that have identical N-termini, including an ER 
targeting sequence, but different properties due to the inclusion of various exons at their 
C-termini that encode the ability to bind heparin and heparin-sulfate containing proteins. 
This is an important property that distinguishes the isoforms from each other as it impacts 
their ability to diffuse away from the cells or become associated with the extracellular 
matrix (ECM). As shown in Figure 1-1 the heparin-binding region for VEGFA is largely 
encoded by exons 6 and 7. Most cell types produce several VEGF isoforms 
simultaneously, although, 121, 165 and 189 are the predominant ones.  VEGF145 has  
                                                 
 
1 Parts of this chapter were adapted with permission. Pereira, E., Preston, A. and 
Hendershot, L.M., UPR Activation in Cancer Cells: A Double-Edged Sword, in 
Endoplasmic Reticulum Stress in Health and Disease, 2012, Springer. In press [3].  
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Figure 1-1. Gene structure of human VEGFA. (A) VEGFA spans 16,272 bp of chromosome 6p12 and consists of eight 
exons. (B) Alternate 5' and 3' splice sites in exons 6, 7 and 8 generate multiple isoforms  (C) Table indicating if the various 
VEGF isoforms can bind heparin or not.  Adapted with permission. Nowak, D.G., J. Woolard, E.M. Amin, O. Konopatskaya, 
M.A. Saleem, A.J. Churchill, M.R. Ladomery, S.J. Harper, and D.O. Bates, 2008. Expression of pro- and anti-angiogenic 
isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of cell science. 121: 3487-95 [6]. 
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restricted expression, and is produced mainly by cells derived from reproductive organs. 
There are two receptor tyrosine kinases (RTKs), VEGFR1 and VEGFR2 that can bind  
VEGFA on their immunoglobulin-like extracellular domains. Early studies identified 
VEGF binding to its receptors located on endothelial cells in vitro and in vivo, however, 
it is now clear that VEGF receptors are also found on bone marrow derived cells. The 
function of VEGFR1 signaling depends on the developmental stage of the animal and the 
cell type. Some of the functions of VEGFR1 signaling are to regulate monocyte and 
macrophage migration, induce expression of MMP9 thus facilitating tumor metastases 
and release growth factors like IL6. VEGFR1 can occur as an alternatively spliced, 
soluble form that negatively regulates the activation and signaling of VEGFR2. Soluble 
VEGFR1 can preferentially bind to VEGFA and thus act as a ‘trap’ and reduce the 
accessibility of VEGFA to bind to VEGFR2. VEGFR1 knockout animals are embryonic 
lethal at E8.5-9.0 due to increased hemangioblast and vascular disorganization.  VEGFR2 
signaling is very important in mediating mitogenic, angiogenic and permeability 
enhancing effects of VEGF. VEGFR2 signaling plays an important role in developmental 
angiogenesis, vasculogenesis and hematopoiesis. VEGFR2 knockout animals are also 
embryonic lethal at E8.5-9.5 due to defective blood-island formation and vasculogenesis 
[7]. 
 
 
Regulation of VEGF Expression 
 
The HIF (hypoxia inducible factor) pathway is the best-characterized cellular 
stress pathway that leads to the up-regulation of proangiogenic factors in response to 
inadequate oxygen delivery [8]. Transcriptional responses to hypoxia are largely 
regulated by HIF, a heterodimeric protein composed of an oxygen-labile  subunit and a 
constitutively expressed  subunit [9].  There are two  subunit members, HIF1 and 
HIF2, which are continuously synthesized and rapidly degraded under normal 
physiological conditions. The oxygen-dependent degradation of the HIF--subunit is 
mediated by hydroxylation of proline 402 and proline 564 by prolyl hydroxylase domain 
protein 2 [10]. Hydroxylated HIF- binds to von Hippel Lindau tumor suppressor protein 
(VHL), which then interacts with the protein elongin C and recruits the E3 
ubiquitin-protein ligase complex and targets the α subunit for degradation via the 26S 
proteasome [11].  In addition, hydroxylation of asparagine 803 inhibits the interaction of 
the  subunit with its transcriptional co-activators p300 and CREB binding protein [12].  
However, when oxygen supplies are reduced, the activity of the hydroxylase is inhibited.  
As a result, the  subunit is not hydrolylated, does not bind VHL, and is stabilized.  This 
allows it to dimerize with the  subunit and its co-activators, and the resulting complex 
(HIF-1 or HIF-2) binds to hypoxia-responsive elements (HRE) on the 5’ flanking region 
of target genes like VEGF and increases its transcription [13]. In addition to the HIF 
pathway playing an essential role in some normal physiological processes like 
development of the embryo and erythropoiesis, there is also a vast amount of data 
demonstrating that it contributes to a number of disease states like cancer, ischemia and 
inflammation [13]. 
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In addition to hypoxia leading to a HIF-dependent transcriptional up-regulation of 
VEGF, there are data demonstrating that the VEGF transcript can be stabilized by 
hypoxia [14].  This post-transcriptional mechanism of inducing VEGF mRNA is due to a 
hypoxia-induced protein complex bound to the VEGF 3’-UTR that mediates increased 
stability. Other HIF-independent post-transcriptional mechanisms for increasing VEGF 
expression have been reported. There are data showing that the stress inducible ER 
chaperone ORP150/GRP170 plays a role in post-translational processing/secretion of 
VEGFA [15].  Ectopic expression of ORP150 in C6, rat glioma cells, increased VEGFA 
secretion, whereas decreasing ORP150 levels with an antisense construct resulted in the 
retention of VEGFA in the ER.  Furthermore, tumors arising from the antisense ORP150 
C6 glioma transfectants demonstrate an initial phase of growth comparable to the 
wild-type glioma cells, which was followed by marked regression and decreased 
angiogenesis within 8 days [15]. 
 
 
The Unfolded Protein Response 
 
In addition to inadequate vascularization of tissues impinging on oxygen delivery 
to cells, this condition can also inhibit the delivery of nutrients like glucose and the 
removal of acidic waste products.  These changes in the extracellular environment of 
cells alter the normal homeostasis of the endoplasmic reticulum (ER), which disrupts 
folding and processing of secretory pathway proteins and leads to the accumulation of 
unfolded proteins in this organelle [16]. This activates the UPR; a complex signal 
transduction pathway that is largely cytoprotective and aims to decrease the detrimental 
effects of accumulated unfolded proteins.  If normal homeostasis is not restored during 
prolonged stress conditions, the UPR can induce apoptosis in these cells in order to 
protect the organism [17]. 
 
The UPR was first delineated in yeast as a relatively simple signaling pathway 
[18].  In higher eukaryotes this cellular stress pathway is mostly conserved but greatly 
expanded and far more complex (Figure 1-2).  In mammalian cells there are three 
transmembrane proteins that sense ER stress through their luminal domains and activate 
downstream responses through their cytosolic domains.  Ire1 was the first to be identified 
based on its homology to the yeast ER kinase that is the single UPR transducer in this 
organism [19].  On sensing stress in the ER, Ire1’s kinase activity is activated, which in 
turn activates an endonuclease activity in its C-terminus that excises 26 nucleotides from 
the X-box binding protein-1 (XBP-1) transcript.  After religation, the resulting frameshift 
encodes an active transcription factor XBP-1(S) that regulates the expression of several 
downstream elements of the UPR [20, 21].  In addition to Ire1 signaling, mammalian 
cells also transiently inhibit cap-dependent translation through activation of a PKR-like 
ER localized kinase (PERK).  Activated PERK phosphorylates eIF2α, which inhibits 
loading of the 80s ribosomal complex on mRNAs.  The resulting inhibition of protein 
translation leads to a loss of cyclin D1 from cells causing a G1 arrest [22], thus 
preventing the proliferation of cells experiencing stress. Contrary to the global inhibition 
of translation in PERK-activated cells, synthesis of the ATF4 transcription factor is  
  5
 
 
 
Figure 1-2. Components of the mammalian ER stress response. The accumulation 
of unfolded proteins in the ER leads to the activation of three ER membrane proteins 
Ire1, PERK, and ATF6 that act as signal transducers. These three arms of the response 
are largely cytoprotective and serve to regulate downstream targets which are ultimately 
responsible for the up-regulation of ER chaperones, inhibition of translation, cell cycle 
arrest, and a number of other transcriptional responses.  
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increased [23]. ATF4 transactivates expression of genes such as CHOP [24], which is 
proapoptotic [25], and GADD34, which is a regulatory subunit of the PP1 phosphatase 
that dephosphorylates eIF2α allowing translation to resume [26]. PERK also activates 
NFκB expression [27], which positively regulates anti-apoptotic proteins like Bcl-2  
during ER stress, thus contributing to the balance between survival and death signals. 
ATF6, which is the third arm of the UPR pathway, is a bZIP transcription factor. ATF6α 
and β are ER-associated transmembrane proteins with lumenal stress sensing domains 
[28]. Upon activation, the ATF6 proteins are transported to the Golgi and cleaved by S1P 
and S2P proteases.  The cytosolically oriented transcription factor domain is liberated and 
regulates the transcription of XBP-1 and other important ER chaperones [29]. These 
signal transducers collectively act to protect the cell during stress conditions by 
increasing the expression of chaperones that enhance the folding capacity of the ER, by 
transiently inhibiting protein translation to decrease the load of unfolded proteins, and by 
increasing the degradative capacity of the cell. If stress conditions do not subside, the 
UPR activates ER localized caspase-4/12 [30, 31] to eliminate cells experiencing 
prolonged stress and ultimately protecting the organism. 
 
 
Cancer cell metabolism is regulated partly by cues from the tumor 
microenvironment 
 
Once tumor cells accumulate mutations in genes that enable them to bypass cell 
cycle checkpoints, apoptotic pathways and in some cases alter cancer cell metabolism, 
increasing studies show that the heterogeneous tumor microenvironment also contributes 
to the metabolic phenotype of cancer cells [32]. Normally non-dividing, differentiated 
cells rely primarily on mitochondrial oxidative phosphorylation to generate energy 
required for various cellular processes, although under reduced levels of oxygen, or 
anaerobic conditions, they can convert glucose to lactate to supply their energy needs 
through a process known as glycolysis.  However, proliferating cells, including cancer 
cells, usually metabolize glucose through aerobic glycolysis to produce energy even 
when oxygen levels are sufficient.  Glycolysis is an inefficient way to generate energy as 
the metabolism of glucose to lactate generates only 2ATPs (adenosine 5’-triphosphate) 
per molecule of glucose whereas oxidative phosphorylation generates 36 ATPs from one 
molecule of glucose [33]. The reason for tumors and other proliferating cells to switch to 
an inefficient method for generating energy that would seem to be contrary to their 
requirements has been unclear.  However, recent studies propose that this phenomenon 
known as the “Warburg effect” results in the production of metabolic byproducts from 
glycolysis, such as nucleotides, amino acids and lipids, that may be beneficial to cell 
proliferation [33].  Due to the highly proliferative nature of tumor cells, the ability to 
metabolize nutrients in a manner conducive to producing new cells rather than efficient 
energy production may provide an explanation of why cancer cells shift over to 
glycolysis. The shift in cancer cell metabolism is a powerful tool used in the clinic to 
image tumors with increased glucose uptake through the use of 18F-deoxyglucose 
positron emission tomography (FDG-PET). Increased glucose uptake in tumors correlates 
with poor prognosis and higher metabolic rate, which is suggested to contribute to a 
malignant phenotype in several tumor types [34].  
  7
Role of HIF pathway in tumor angiogenesis 
 
Angiogenesis is a complex process that requires multiple gene products regulated 
by different cell types to converge and stimulate blood vessel formation. Hypoxia plays a 
major role in regulating a large number of genes involved in different steps of 
angiogenesis including, upregulating expression of various growth factors like VEGF, 
fibroblast growth factor and angiopoietins. This stress pathway also has the ability to 
induce endothelial cell migration and tube formation in tissue culture. In addition to its 
role in regulating molecular determinants of angiogenesis in culture, the HIF pathway 
also plays an important role in tumor angiogenesis. Up-regulation of the HIF pathway in 
solid tumors is via a combination of limited oxygen supply in the microenvironment and 
genetic mechanisms. The HIF pathway can be induced by several growth-promoting 
stimuli and oncogenic pathways that are up-regulated in tumors like insulin, insulin-like 
growth factor-1, epidermal growth factor and mutant Ras and src kinase pathways. 
Mutation in several tumor suppressor genes like pVHL, PTEN, p53 and p14ARF activate 
the HIF pathway. Given that the HIF pathway plays a role in regulating multiple steps of 
the angiogenic process and this pathway is activated in tumors, it is plausible that the HIF 
pathway could be used as a potential anticancer target [35]. However, the effects of 
inactivating the HIF pathway in embryonic stem cell derived teratomas have been 
variable, with neither vascularity nor growth being correlated with an intact HIF system 
in every study conducted [36-38]. Another study engineered an inducible knockdown of 
HIF1 in D54-a glioblastoma cell line and observed that inhibition of HIF1 during the 
early-stages of tumor development is more efficacious at decreasing tumor burden when 
injected in the flank of the animal.  Inhibition of HIF1 at the late-stages in tumor 
development had no significant effect. The same study used a different tumor model and 
showed that HIF1 plays no role in regulating the growth of tumors derived from MDA-
MB435- cell line. On further investigation, the authors observed that the tumors derived 
from MDA cell line were still responsive to hypoxia, however, VEGF secretion in this 
line was through a HIF-independent mechanism making them unresponsive to inhibition 
of HIF1 [39]. 
 
 
Is the tumor dependence on UPR activation due to it having a role in angiogenesis?  
 
Once tumor cells acquire the necessary mutations to overcome cell cycle 
checkpoints and interfere with apoptotic pathways, limitations in their extracellular 
environment can pose the next hurdle to uncontrolled cell growth.  The rapid division and 
high metabolic rate of many tumors increases their demand for essential nutrients and 
oxygen, which is further exacerbated as their growth increases the distance of some cells 
within the tumor mass from existing vasculature [4] as illustrated in Figure 1-3.  Indeed, 
unless the tumor is able to rectify this situation, it enters a dormant state [40].  The 
presence of hypoxic cells in localized regions of solid tumors is well documented 
clinically and experimentally.  Perhaps counter intuitively this is correlated with a more 
aggressive phenotype and a poorer prognosis [41], which in part stems from the fact that 
cytoprotective signal transduction pathways, including the UPR, are activated by these  
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Figure 1-3. Tumor angiogenesis is regulated by multiple stress pathways activated 
in cancer cells. Rapidly proliferating tumor cells have an increased demand for nutrients, 
ATP and oxygen due to a high metabolic rate (green). As the tumor mass grows in size, 
cells that are more distant from a functional blood vessel are deprived of nutrients and 
oxygen and become hypoxic (blue). Tumor cells adapt to these adverse conditions by 
activating stress signaling pathways like the UPR and HIF. The UPR has several 
protective functions that assist tumor cell survival, including up-regulation of several 
proangiogenic factors such as VEGF by UPR-inducible transcription factors XBP1(S) 
and ATF4.  Activation of the HIF signaling pathway stabilizes HIF1 and HIF2, which 
can transactivate VEGF gene expression during hypoxic/anoxic conditions.  The UPR 
and HIF signaling pathways are thus both likely to contribute to angiogenesis and tumor 
growth. 
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conditions.  Unlike HIF pathways that are only activated in regions of the tumor that are 
further than approximately 0.2 mm from blood vessels [1], the UPR appears to be 
activated through out tumor masses due to their high metabolic rates, which might 
suggest that different subsets of cells within the tumor may experience different 
combinations of these two stress pathways.  Our studies will assess the contribution of 
these pathways in regulating VEGF expression in cells experiencing both stresses. 
 
To elucidate the role of Ire1 in regulating tumor growth and angiogenesis in vivo, 
two separate studies engineered U87 human glioma cells with either an Ire1 dominant 
negative mutant or a control empty vector and then orthotopically implanted them in 
mice [42, 43].  In both studies, tumors derived from cells expressing the Ire1-dominant 
negative mutant were significantly smaller, less vascularized but more highly infiltrative 
as compared to their control counterparts.  Similar results were obtained using a chick 
chorio-allantoic membrane (CAM) assay [43].  Although blocking the expression of Ire1 
in tumor cell lines introduced into animals resulted in the inhibition of 
neovascularization, somewhat counter-intuitively it also modified the growth 
characteristics of the cells and promoted tumor cell invasion.  This highly 
infiltrative/avascular phenotype has been reported by several other laboratories in 
response to various methods of blocking angiogenesis, although the molecular 
mechanism for this striking phenotype is still unknown.  Supporting data for the role of 
Ire1 in tumor growth came from a study where Ire1’s downstream target XBP-1 was 
examined using transformed XBP-1 wild-type and null MEFs.  In this case, the XBP-1 
null cells severely impeded tumor growth.  When extreme hypoxic conditions were used 
to activate the UPR in the two cell lines, the XBP-1 null cells had a higher rate of 
apoptosis and decreased survival, in keeping with their failure to grow in mice.  However 
the secretion of the proangiogenic factors VEGF and FGF2 under these culture conditions 
at shorter times was not significantly different between the two lines, leading the 
investigators to conclude that failure to induce angiogenesis was unlikely to be the reason 
the XBP-1 null cells failed to form tumors.  Instead, they hypothesized that the 
Ire1/XBP-1 axis contributed to tumor cell survival via a mechanism that remained to be 
elucidated [44].  It should be noted however that the extreme hypoxic conditions used in 
these cell culture assays would be expected to also activate the HIF pathway, which is not 
expected to be affected by deletion of XBP-1, although this has not been formally tested.  
These results suggests the possibility that in tumors, the UPR may play as large or larger 
role than the HIF pathway in promoting angiogenesis and survival, due to the fact that 
more cells within the tumor may have activated the UPR. 
 
Cells cultured under hypoxic/anoxic conditions also activate the PERK branch of 
the UPR, which controls a translational inhibition program that is shared with other stress 
signaling pathways that use distinct eIF2 kinases, and is therefore known as the 
integrated stress response (ISR).  In addition to the transient inhibition of protein 
synthesis that is a hallmark of PERK activation, a number of transcription factors are up-
regulated that are responsible for many of the changes observed in the ISR.  One of these 
factors is ATF4/ cyclic AMP (cAMP)-responsive element binding protein 2 that regulates 
the ISR and protects the cell against metabolic consequences of ER stress [45]. To 
determine if the PERK pathway might also contribute to tumor survival, K-ras 
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transformed PERK wild-type and null MEFs were injected into the flank of athymic 
Nu/Nu mice. These studies show that tumors derived from K-ras-transformed PERK null 
MEFs are smaller and exhibit less angiogenesis than tumors from cells that express 
PERK.  These studies also revealed that PERK activation favors endothelial cell survival 
and functional blood vessel formation in a tumor microenvironment by preferentially up-
regulating expression of proangiogenic factors like VCIP, an adhesion molecule that 
facilitates integrin binding, cellular adhesion and capillary morphogenesis [46].  
 
 
UPR activation regulates other proangiogenic factors 
 
Although VEGF is the most potent proangiogenic factor, there are other factors 
including FGF2, IL8, IL6, VCIP, and angiogenin that play a role in promoting 
angiogenesis [47].  Microarray analysis of polysome-bound RNA demonstrated that a 
subset of proangiogenic transcripts including VCIP, an adhesion molecule that promotes 
capillary morphogenesis, is preferentially translated in a PERK-dependent manner [46].  
In a mouse model of pancreatic islet carcinoma, increased expression of several 
Fibroblast Growth Factor (FGF) family members including FGF2 is observed when the 
binding of VEGF to its receptor-VEGFR2 is inhibited by a monoclonal anti-VEGFR2 
antibody [48].  Anti-VEGFR2 is currently used to inhibit angiogenesis in the treatment of 
some cancers.  A clearer understanding of the compensation mechanisms that exist 
between proangiogenic factors is important for the development of therapeutic agents.  
IL8, FGF2 and angiogenin are induced by different stress conditions including, hypoxia 
and low glucose [49].  It has been reported that hypoxia can induce IL8 expression in a 
HIF-1 deficient colon cancer cell line.  This induction was mediated by enhanced 
production of ROS and activation of NFB [50].  Since NFB can be activated 
downstream of PERK [27], it is conceivable that UPR activation can induce IL8 
expression via this transcription factor. 
 
In summary, when I began my dissertation studies, there were preliminary data 
from a microarray study conducted in our lab to suggest that UPR activation can promote 
the expression of a significant number of proangiogenic factors in cultured cells [49]. I 
wanted to understand how many of these factors are UPR targets. We then focused on 
understanding the regulation of the most potent and best characterized proangiogenic 
factor- VEGF by the UPR. It was important to determine which UPR-inducible 
transcription factor played a critical role in regulating its expression. The fact that tumors 
activate both HIF and UPR pathways raises the questions of which pathway is most 
critical in promoting angiogenesis (Figure 1-4), whether different cells within the tumor 
mass rely on distinct pathways, and what affect will dismantling the UPR have on VEGF 
production in a tumor model. These studies will determine if the UPR might represent a 
druggable pathway for inhibiting angiogenesis and treating cancer. 
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Figure 1-4. Regulation of angiogenic factors by stress-activated pathways. 
Angiogenesis is regulated by a fine balance between proangiogenic factors (red circles) 
and antiangiogenic factors (blue circles) under normoxic conditions.  The UPR is a 
positive regulator of angiogenesis, since its activation increases expression of 
proangiogenic factors and inhibits anti-angiogenic factors. The HIF signaling pathway 
also increases expression of proangiogenic factors under hypoxic conditions.  Since 
certain regions of the tumor mass encounter environmental conditions that lead to the 
activation of both pathways, UPR and HIF, it is conceivable that they could either 
synergize or compete to increase expression of proangiogenic factors. 
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Specific Aims 
 
Aim 1:  To determine the role of the UPR in regulating the expression of 
proangiogenic factors and identify the mechanism(s) and critical signaling components of 
the response that do so.  Preliminary microarray analysis on Daoy, a human 
medulloblastoma cell line, treated with thapsigargin, an UPR stress inducer, showed that 
in addition to increased expression of known UPR target genes there was an up-
regulation of several proangiogenic factors including, VEGFA, IL-8, FGF2 and 
angiogenin. Studies outlined in this aim will: 
 
a) Determine the extent proangiogenic factors affected by ER stress. 
b) Confirm these findings by real-time PCR and extend them to other UPR inducers 
and other types of cell lines. 
c) Determine the mechanism(s) by which VEGF, the best-characterized and most 
important proangiogenic factor, is regulated by the UPR. 
d) Identify the UPR-induced transcription factors that contribute to VEGF 
expression. 
 
Aim 2:  To determine the relative importance of the UPR versus HIF signaling in 
regulating VEGF expression in cultured human cells. Solid tumors activate multiple 
signaling pathways simultaneously including the UPR and HIF 
In order to determine the contribution of these two pathways to VEGF expression, we 
will: 
 
a) Establish the fold induction of VEGF with the two stresses alone and in 
combination. 
b)  Identify the UPR-induced transcription factor(s) that regulate VEGF in response 
to ER stress. 
c) Determine the effects on pathway-specific transcription factors in binding to the 
VEGF promoter when both stresses are present. 
d) Assess to what extent each pathway contributes to VEGF expression under 
conditions of hypoxia and ER stress. 
 
Aim 3:  To determine the importance of the UPR in regulating tumor 
angiogenesis in vivo. Once we have identified the critical UPR-inducible transcription 
factor(s) that regulate expression of VEGFA in cultured cells, we wish to determine the 
relative effect of the UPR in contributing to angiogenesis in a xenograft model.  To do so, 
we will: 
 
a) Engineer human cell lines in which the critical UPR-regulated transcription 
factor(s) can be conditionally knockdown. 
b) Determine the effects of inhibiting expression of the transcription factor on tumor 
cell line growth in culture and in animals. 
c) Perform xenograft studies to assess its contribution in mediating angiogenesis in 
an animal model. 
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CHAPTER 2.    THE UNFOLDED PROTEIN RESPONSE POSITIVELY 
REGULATES PROANGIOGENIC FACTORS2  
 
 
Introduction 
 
Changes in the extracellular environment of a cell can adversely affect the normal 
homeostasis of the endoplasmic reticulum (ER), which disrupts the folding and 
processing of secretory pathway proteins.  The resulting accumulation of unfolded 
proteins in the ER increases the demands for molecular chaperones and folding enzymes 
and activates a signal transduction cascade known as the unfolded protein response 
(UPR) [51].  This multi-component signal transduction pathway is largely cytoprotective; 
serving to decrease the detrimental effects of accumulated unfolded proteins by 
increasing molecular chaperones that bind to them, decreasing protein synthesis to limit 
the accumulation, and finally increasing the degradative capacity of the cell to eliminate 
them.  However if normal homeostasis is not restored during prolonged stress conditions, 
the UPR can induce apoptosis in these cells in order to protect the organism [51, 52].  In 
mammalian cells, the UPR is controlled by three resident ER transmembrane proteins 
that “sense” ER stress and activate signals to downstream elements; Ire-1, PERK and 
ATF6. Ire-1 is an ER localized transmembrane protein, which has a kinase and 
endoribonuclease domain in its cytosolic tail.  On sensing ER stress, Ire-1 is 
phosphorylated in trans, which in turn activates its endonuclease domain leading to the 
excision of 26 bases from the X-box binding protein (XBP-1) transcript [53].  The 
resulting frame shift encodes a fully active transcription factor XBP-1(S), which 
up-regulates expression of a number of resident ER proteins that contribute to folding or 
degradation of unfolded or misfolded proteins [21, 54].  In addition to Ire-1 signaling, 
mammalian cells also transiently inhibit cap-dependent protein translation and arrest cells 
in the G1 phase of the cell cycle through activation of the PKR-like ER kinase (PERK) 
[23, 55].  Contrary to this global inhibition in protein translation occurring in PERK-
activated cells, synthesis of the ATF4 transcription factor is increased during ER stress 
[23].  ATF4 transactivates expression of a number of genes including CHOP [56], a 
pro-apoptotic protein, and GADD34 [26], which reverses the block in translation.  PERK 
also activates NFκB [27], a pro-survival protein, thus contributing to the balance between 
survival and death signals.  Lastly, activation of ATF6 results in its translocation to the 
Golgi and cleavage by the S1P and S2P proteases to release the cytosolically oriented 
active transcription factor that up-regulates expression of XBP-1, as well as folding 
enzymes and ER chaperones, such as PDI and BiP [57, 58].  
 
In addition to protecting cells during physiological and chemical conditions that 
adversely affect protein folding in the ER, there is increasing evidence to show that the 
UPR also plays an important role in normal development and physiology.  This includes 
                                                 
 
  2 This chapter was adapted with permission. Pereira, E.R., N. Liao, G.A. Neale, and L.M. 
Hendershot, 2010. Transcriptional and post-transcriptional regulation of proangiogenic 
factors by the unfolded protein response. PloS one. 5 [49].  
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liver development [59],  plasma cell differentiation [60, 61], bone development [62, 63], 
and normal pancreatic homeostasis [64].  Mice that are null for either XBP-1 [59] or its 
upstream activator Ire1α [65-68] die at day E12.5 due to hepatoinsufficiency.  In both 
cases, this was later confirmed to be due to an inability to produce XBP-1(S), a major 
regulator of hepatic development.  In addition to liver, pancreas, and muscle, XBP-1(S) is 
also highly expressed in the placenta [65], and Ire1α null embryos show evidence of 
placental abnormalities.  To determine the role of Ire1 in this tissue, a recent study 
generated mice lacking Ire1α by crossing Ire1α+/- mice with Mox2+/Cre transgenic mice 
[65].  Mox2 is ubiquitously expressed except in the labyrinthine trophoblasts of the 
placenta.  This allowed Ire1-deficient embryos to be produced that have normal levels of 
Ire1 in the placenta [65].  This study revealed that loss of Ire1α in the placenta led to 
decreased vascular endothelial growth factor (VEGFA) production, which is a major 
inducer of angiogenesis, thereby resulting in severe dysfunction of this highly 
vascularized tissue.   
 
Angiogenesis refers to the sprouting, migration and remodeling of existing blood 
vessels [69] and plays an important role in a number of normal physiological processes 
including embryonic development, wound healing, and the female reproductive cycle.  It 
also plays a role in several pathological conditions including ischemia and cancer.  
Angiogenesis is regulated by a fine balance between factors that stimulate the formation 
of new blood vessels and those that inhibit it [70, 71].  Proangiogenic factors such as 
VEGF, fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), and 
IL8 are released by cancer cells experiencing decreased oxygen and nutrient supplies [72-
74].  These factors act as ligands that bind to specific receptors on endothelial cells, 
causing them to proliferate and to release matrix metalloproteinases that degrade the 
extracellular matrix, allowing them to migrate toward the angiogenic stimulus in order to 
establish new blood vessels [72].  The predominant and best studied proangiogenic factor 
is VEGFA, a homodimeric heparin binding glycoprotein that is produced in several 
isoforms due to alternative splicing.  The different isoforms of VEGFA (206, 189, 165, 
145 and 121) have varying expression patterns and contrasting properties [75].  Of these 
VEGF165 is the predominant and best characterized isoform, and plays an important role 
in mediating angiogenesis [76].  All VEGF isoforms are synthesized and processed in the 
endoplasmic reticulum (ER) and transported through the secretory pathway [72, 77].    
 
The HIF (hypoxia inducible factor) pathway is the best characterized cellular 
stress pathway that leads to the up-regulation of proangiogenic factors in response to 
inadequate oxygen delivery [78].  HIF-1 and HIF-2 are heterodimeric transcription 
factors consisting of an oxygen-labile α subunit and a constitutively expressed β subunit.  
Hypoxia stabilizes the α subunit, thereby activating the HIF complex, which in turn binds 
to the promoters of target genes such as VEGF and other proangiogenic factors and 
transactivates them [79]. Prolonged hypoxia can also increase VEGFA mRNA stability 
leading to further increases in VEGFA production [80].  In addition to the role of the HIF 
signaling pathway in up-regulating VEGF expression, several recent studies demonstrate 
that the UPR also contributes to VEGF transcription [81] and protein processing in the 
ER [15].  Using microarray analysis, we found that in addition to VEGFA a large number 
of proangiogenic factors were up-regulated by UPR inducers.  The up-regulation of 
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several of these factors by ER stress was as robust as, or even greater than, that achieved 
with hypoxia.  We found that two UPR-regulated transcription factors bound directly to 
the VEGFA promoter in response to ER stress and contributed to its transcription.  In 
addition, activation of AMP kinase stabilized the VEGFA transcripts, further contributing 
to VEGFA mRNA levels.  Our finding that a number of regulators of angiogenesis are 
targets of the UPR argues that this physiological process should be added to the growing 
list of normal homeostatic and developmental processes that this stress pathway controls. 
 
 
Results 
 
 
UPR activation results in the transcriptional up-regulation of a number of 
proangiogenic factors 
 
We wished to characterize the UPR in a solid tumor cell line that could ultimately 
be used in xenograft studies to ensure that this stress response was fully active and that all 
branches were intact.  To do so, we treated Daoy, a human medulloblastoma cell line 
with thapsigargin, a Ca2+ ATPase inhibitor and potent inducer of the UPR, and performed 
genome-wide microarray analyses.  Overall, we identified 1069 probe sets with 
differential expression after either 3 or 8 hours of thapsigargin treatment compared to 
untreated cells.  Further analysis of this data confirmed significant enrichment of the 
expected UPR target genes, including ER chaperones, folding enzymes, and proteins 
involved in ER associated degradation (ERAD), as well as the transcription factors that 
are known to up-regulate them in response to ER stress.  In addition to UPR targets, 
somewhat unexpectedly, gene ontology analysis revealed a significant enrichment of 
genes associated with the regulation of angiogenesis.  A total of 185 genes on the array 
are annotated as being associated with angiogenesis.  As many of these encode 
endothelial cell-specific proteins or cell surface receptors on endothelial cells, we limited 
our further analysis to the 33 genes that are secreted proteins or transcription factors that 
either positively or negatively regulate angiogenesis.  Of the 19 genes that are 
characterized as positive regulators of angiogenesis, 13 showed a greater than 2-fold 
increase in expression in at least one time point after thapsigargin-treatment (Table 2-1).  
Additionally expression of one negative regulator of angiogenesis, vasohibin (VASH1) 
was decreased with ER stress.  These data suggest that regulating angiogenesis is likely 
to be a major function of the UPR.  
 
 
Comparison of UPR inducers with hypoxia in the up-regulation of proangiogenic 
factors 
 
To confirm the induction of proangiogenic factors by the UPR, we treated cell 
lines with UPR inducers and compared the magnitude of their induction to that achieved 
with conditions that activate the HIF pathway using quantitative Real-Time PCR 
(qRT-PCR) (Figure 2-1).  We confirmed by western blot analyses that CoCl2 and the 
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Table 2-1.   UPR activation enhances expression of proangiogenic factors. 
 
   Fold Change  
Gene Symbol Gene Name Angiogenic 3 Hour 8 Hour 
ANG Angiogenin Positive 2.4 8.1 
ANGPT2 Angiopoietin-2 Positive -2.6 2.2 
CTGF Connective tissue growth factor Positive 2.2 1.4 
EPAS1 Endothelial Pas domain protein 1 Positive 1.8 2.6 
EREG Proepiregulin Positive 2.3 6.3 
FGF2 Fibroblast growth factor-2 Positive 1.5 3.1 
F3 Thromboplastin Positive 2.9 1.6 
IL1A Interleukin-1 α Positive 4.4 10.8 
IL6 Interleukin-6 Positive 4.8 7 
IL8 Interleukin-8 Positive 54.25 27.9 
KLF5 Kruppel-like factor 5 Positive 2.6 3.5 
TGFB2 Transforming growth factor beta-2 Positive 4.1 2.9 
VEGFA Vascular endothelial growth factor A Positive 1.7 2.7 
VASH1 Vasohibin Negative -1.3 -3 
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Figure 2-1. Up-regulation of proangiogenic factor mRNA by the UPR and 
hypoxia.  Daoy, NB1691, SKNAS, C6 and NIH3T3 cells were treated with 100 µM 
CoCl2, 1% O2 hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no 
glucose media (No Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and 
mRNA fold induction relative to the untreated control sample, which was set to 1, was 
determined for (A) VEGF (white bars) (B) angiogenin (striped bars) (C) FGF2 
(chequered bars)  and (D) IL8 (grey bars). Experiments were performed in triplicate 
(values are mean ± SD). 
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level of hypoxia (1% O2) used in our experiments induced HIF1α and BNIP3, its 
downstream target, but did not induce UPR targets. Importantly, the UPR inducing agents 
did not activate the HIF signaling pathway (Figure A-1).  Thus the conditions we used in 
our analysis allowed us to specifically activate these two stress pathways independently.  
Five different cell lines were treated with a variety of UPR inducers (e.g., tunicamycin, 
thapsigargin, and no glucose) and with two different inducers of the HIF pathway (e.g., 
CoCl2 and 1% oxygen) for 24 hours, and the induction of four of the best characterized 
proangiogenic factors: VEGFA, bFGF, angiogenin and IL8 was measured.  We also 
confirmed that downstream UPR target genes like CHOP and BiP mRNA were up-
regulated by ER stress in each of the cell lines tested (Figure A-2).  As expected, all four 
factors were up-regulated by hypoxic conditions, although the magnitude varied 
dramatically between cell lines, largely due to differences in their basal levels of 
synthesis (Figure A-3).  When UPR inducers were used, we found that in many cases the 
induction of the four proangiogenic factors was nearly as high as or even higher than that 
achieved with hypoxia, although there were some interesting differences.  Hypoxia was a 
strong inducer of VEGFA mRNA in the NB1691 neuroblastoma cell line, while ER stress 
had little effect on VEGFA levels.  Conversely ER stress induced VEGFA in the NIH3T3 
fibroblast line, but hypoxia did not (Figure 2-1A).  Similarly ER stress induced FGF2 
expression greater than hypoxia in the Daoy line, whereas neither stress condition 
stimulated its production in the C6 and NIH3T3 cell lines, perhaps due to the high levels 
of basal expression of FGF2 in these two lines (Figure 2-1C).  In keeping with the 
microarray data, angiogenin was modestly induced in the Daoy cell line and the NB1691 
line, but in the other three lines there was very little effect with either hypoxia or ER 
stress inducers (Figure 2-1B), again in keeping with higher basal levels in these lines.  
Finally, increases in human-specific IL8 expression were much more dramatic with ER 
stress than with hypoxia in all three human cell lines (Figure 2-1D).  
 
 
UPR activation increases VEGFA mRNA stability via AMPK   
 
In this study we focused on determining the mechanism by which the UPR 
regulates VEGFA expression, as VEGFA is the best characterized stimulator of 
angiogenesis and represents a therapeutic target for treating cancer as well as several 
ischemic, infectious and inflammatory disorders [82].  Additionally, we favored this 
target because in most of the lines we examined, including mouse cells, VEGFA was 
induced to higher levels with ER stress than with hypoxia.  We chose the C6 cell line for 
these experiments, because it had a low basal expression of VEGF which was potently 
induced by ER stress, previous studies used this line to study VEGF gene regulation by 
hypoxia, and this line was used in xenograft studies to determine the role of 
ORP150/GRP170 in VEGF processing and and secretion.  VEGFA mRNA levels increase 
in response to hypoxic conditions via a combination of an enhanced transcription at early 
time points coupled with an increase in the stability of the mRNA at later times [83].  To 
investigate whether UPR activation might also increase VEGFA mRNA stability, we 
examined the turnover of VEGFA mRNA under control and various stress conditions 
(Figure 2-2A).  Cells were pretreated with hypoxia or two different UPR  
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Figure 2-2. UPR activation stabilizes VEGF mRNA via AMPK.  (A)  C6 cells were 
pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-square), thapsigargin 
(Tg-triangle), or no glucose media (No Glu-cross) for 6 hours. Actinomycin D (5 µg/ml) 
was added to the various cultures to block further transcription. At the indicated times, 
total RNA was extracted and subjected to qRT-PCR to determine VEGF mRNA levels. 
The mean values of data from duplicate experiments are presented (± SD). (B) C6 cells 
were either left untreated or treated as indicated in the figure in the presence or absence 
of Compound C for 9 hours or 14 hours. Western blot analysis was performed on cell 
lysates to determine levels of p-AMPK. Hsc70 was used as loading control. (C-D) C6 
cells were pretreated with different stress inducers for 6 hours as indicated. No inhibitor 
(black) or compound C (AMPK inhibitor- white) was added to the cells as indicated for 
an additional 8 hours. Total RNA was extracted for qRT-PCR to determine VEGF mRNA 
(C) and VEGF hnRNA (D) levels. Experiments were performed in triplicate (values are 
mean ±SD). 
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inducers and then incubated with actinomycin D to inhibit further transcription.  In 
control cells the low level of basal transcripts were rapidly degraded in keeping with 
previous studies [80, 84].  For all three stress inducers, there was a reproducible increase 
in VEGFA mRNA at 30 minutes after adding actinomycin D, which is compatible with an 
increase in transcription occurring before the inhibitor takes effect.  We found that 
although hypoxic conditions led to an initial increase in VEGFA levels, the mRNA was 
rapidly degraded.  This is consistent with a previous report using C6 cells, which showed 
that hypoxia had no significant effect on the half-life of VEGFA mRNA until much later 
time points [83].  When cells were pretreated with the two UPR inducers, we found that 
after the initial burst in VEGFA transcripts they decayed significantly slower than in 
control or hypoxia-treated cells. (Figure 2-2A), arguing that ER stress leads to increased 
VEGFA mRNA stability at relatively early times in the response.  
 
The increase in VEGFA mRNA stability observed after prolonged exposure to 
hypoxic conditions is due to the binding of a hypoxia-inducible protein complex, such as 
HuR, to the ARE (adenylate-uridylate rich elements) region in the 3’UTR region of 
VEGFA mRNA [80].  Additionally, stress activated protein kinases such as AMPK, 
p38MAPK, JNK, and PI3K have been implicated in increasing VEGFA mRNA stability 
through their action on the AU rich region of the 3’UTR [85-88].  We used a variety of 
kinase inhibitors to determine if any of their targets might play a role in increasing the 
stability of VEGFA mRNA during ER stress.  When the UPR-activated cells were 
incubated with compound C, an AMP kinase inhibitor, there was a significant reduction 
in VEGFA transcripts (Figure 2-2C), suggesting that this kinase played a role in the UPR-
induced stabilization of VEGFA.  Activation of AMPK by ER stress was confirmed by 
western blotting, as was the efficacy of its inhibitor, Compound C (Figure 2-2B).  We 
also co-incubated UPR activated cells with inhibitors of the PI3 and JUN kinases, but 
found that they had no affect on VEGFA mRNA levels in response to UPR activation 
(data not shown).  As an additional control, the effect of the AMPK inhibitor on VEGFA 
mRNA levels was examined in cells pre-treated with hypoxia for 6h (Figure 2-2C), which 
was previously shown to be not long enough to stabilize VEGFA transcripts [83]. 
 
Unexpectedly, we found that VEGFA stability was actually increased in hypoxia 
treated cells that we incubated with Compound C, although we do not understand the 
basis for this effect.  To verify that the effects of this inhibitor was specifically on 
VEGFA mRNA stability and did not alter transcription of the VEGFA gene, we treated 
cells with the various combinations of kinase inhibitor and stress inducers and examined 
heteronuclear VEGFA RNA (hnRNA) levels (Figure 2-2D), which can be used as a 
measure of transcription.  We found that there was no indication that this inhibitor 
affected VEGFA transcription, thus confirming that VEGFA transcripts are stabilized 
during ER stress, which apparently is due to the activation of the AMP kinase.  
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UPR activation increases the transcription of VEGFA  
 
Our analysis of VEGFA hnRNA in the experiment described above revealed that 
the unprocessed hnRNA levels were higher in cells treated with thapsigargin or no 
glucose than in control cells.  This suggested that VEGFA might also be transcriptionally  
regulated in response to ER stress. Prior to using hnRNA levels as a measure of the 
transcription rate, we first confirmed that the splicing of VEGFA mRNA was not 
significantly affected by UPR activation.  Cells were pretreated for 6 hours with the 
indicated stressors, and actinomycin D was added to inhibit further transcription.  
Heteronuclear RNA was then measured at the indicated time points.  We found that 
VEGFA hnRNA decreased at a fairly similar rate in control and stress activated cells 
through at least eight hour of treatment, arguing that these stresses did not dramatically 
affect splicing up to this point (Figure 2-3A). Therefore, the measurement of VEGFA 
hnRNA could be used as an indication of the transcription rate of this gene in response to 
UPR activation (Figure 2-3B).  Cells incubated in media containing no glucose, increased 
VEGFA transcription to a much greater extent than either thapsigargin or hypoxia at all 
time points measured, which is in keeping with the 30 minute time point in Figure 2-2A.  
Thapsigargin was as good as or better than hypoxia at inducing VEGFA transcription 
throughout the course of the experiment.  Thus, the increased transcription rate, coupled 
with the stabilization of VEGFA transcripts, accounts for the higher steady state level of 
VEGFA mRNA in response to thapsigargin compared to hypoxia in this cell line (Figure 
2-2A).  Although the transcription rate of VEGFA appeared to be the highest in the 
presence of no glucose, this is not reflected in the steady state levels after 24 hours of 
treatment (Figure 2-2A), which may be due to some inhibition of splicing occurring at 
later time points. 
 
 
XBP-1 binds to two regions in the rat VEGFA promoter 
 
To identify potential binding sites for various UPR-inducible transcription factors, 
we analyzed the human, mouse and rat VEGFA promoters using the computer programs 
rVista and TRANSFAC (Figure A-4).  In addition to HIF sites, the promoters of all three 
species have a number of potential binding sites for the UPR-induced transcription 
factors XBP-1 and ATF4, whereas only the mouse promoter has a single ATF6 site.  We 
first assessed whether XBP-1(S) bound to any of the five potential sites in the rat 
promoter in response to ER stress using a chromatin immunoprecipitation (ChIP) assay, 
since the C6 rat glioma was used for both the mRNA stability and transcription assays.  
Indeed, XBP-1(S) could be detected at two different sites (i.e., one at ~1.9kb and one at 
~5.2kb up-stream of the transcription start site) in response to both thapsigargin and no 
glucose treatment (Figure 2-4B).  We were unable to detect XBP-1(S) binding to the 
remaining three potential sites in these cells upon UPR activation, suggesting that either 
they are not used or that the anti-XBP-1(S) antiserum used to immunoprecipitate the 
chromatin could not gain access to these sites.  As a positive control, we showed that 
XBP-1 binds to the ERdj3 promoter (Figure 2-4C), as documented previously [89].  We 
detected XBP-1(S) protein in ER stressed but not in untreated C6 cell lysates that were 
used for the chromatin immunoprecipitation assays (Figure 2-4D). 
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Figure 2-3. UPR activation increases VEGF transcription rate. (A) C6 cells were 
pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-square), thapsigargin 
(Tg-triangle), or no glucose media (No Glu-cross) for 6 hours as indicated. Actinomycin 
D (5 µg/ml) was added to block further transcription. At the indicated times, total RNA 
was extracted and subjected to qRT-PCR to determine the kinetics of the disappearance 
of VEGF hnRNA in control and stressed cells. (B) C6 cells were untreated (NT-black), 
treated with 1% O2 (Hy-grey), thapsigargin (Tg-striped) or no glucose media (No Glu-
white) for the indicated times. Total RNA was extracted, and VEGF hnRNA was 
quantitated by qRT-PCR. Experiments were performed in triplicate (values are mean 
±SD). 
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Figure 2-4. XBP-1 binds to two regions in the rat VEGF promoter in  
response to ER stress and contributes to increasing VEGF transcription rate. (A) 
Potential XBP-1 sites in the rat VEGF promoter. (B) Cross-linked chromatin from C6 
cells that were untreated (NT), thapsigargin-treated (Tg), or incubated in no glucose 
media (No Glu) for 8hours were immunoprecipitated with anti-XBP-1 or with a control 
antiserum (anti-BiP). Ten-fold serial dilutions of precipitated chromatin and input 
controls were used for PCR amplification. (C) As a positive control, primers spanning the 
XBP-1 binding region on the ERdj3 promoter were used to PCR amplify the anti-XBP-1 
precipitated chromatin (D) XBP-1(S) protein levels were detected in C6 cells treated with 
Tg and No Glu media using Western blot analysis. (E) XBP-1 wild-type (black) or null 
(white) MEFs were untreated (NT), thapsigargin-treated (1µM), treated with media 
lacking glucose (No Glu) or homocysteine-treated (10 mM) for 14 hours. Cell lysates 
were prepared and XBP-1(S) was detected by western blot analysis. (F-G) Cells were 
treated as in (E) and total RNA from the indicated samples was subjected to qRT-PCR to 
quantify VEGF hnRNA (F) or VEGF mRNA (G) at the indicated time points.  RNA 
levels were expressed relative to the control untreated samples for each line, which was 
set to 1. Experiments were performed in triplicate (values are mean ± SD). 
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XBP-1 mediates increased expression of VEGFA following ER stress 
 
To determine the contribution of XBP-1 to the up-regulation of VEGFA 
transcription, we made use of XBP-1 wild-type (XBP-1 wt) and null (XBP-1 ko) mouse 
embryonic fibroblasts (MEFs).  Examination of these cells by western blotting confirmed 
that no XBP-1(S) protein could be detected in the XBP-1 null cells in response to UPR 
induction (Figure 2-4E).  Next we compared the fold induction of both VEGFA hnRNA 
(Figure 2-4F) and VEGFA mRNA (Figure 2-4G) in both cell lines after treating with 
three different ER stress inducers; thapsigargin, no glucose media, and homocysteine.  
Our qRT-PCR analysis in the XBP-1 wild-type MEFs demonstrated an ~10 fold increase 
in VEGFA transcription rate after 8h of either thapsigargin or homocysteine treatment 
(Figure 2-4F); whereas no glucose media was a relatively poor inducer of VEGFA 
transcription in this cell line, perhaps in keeping with the reduced amount of XBP-1(S) 
produced by this stress condition (Figure 2-4E).  The transcription rate was highest at 8h 
for both thapsigargin and homocysteine treatment, demonstrating that its induction is not 
sustained during UPR activation in the wild-type MEFs as was observed in the C6 cell 
line.  This is mirrored in the total mRNA transcripts, which were also higher at 8 hrs of 
stress induction (Figure 2-4G).  When the XBP-1 null cells were similarly examined, we 
found that there was little or no increase in VEGFA transcription with any of the 
treatments, suggesting that XBP-1 played a major role in the up-regulation of VEGFA in 
response to ER stress.  However, closer analysis of the VEGFA hnRNA data from the two 
cell lines revealed that the untreated XBP-1 wild-type MEFs had a lower basal level of 
VEGFA hnRNA than the null cells, (Figure A-5).  Hence, the exact contribution of 
XBP-1 in up-regulating VEGFA was somewhat complicated by the differences in basal 
transcription rates between the two lines. 
 
 
ATF4 contributes to up-regulation of VEGFA expression following UPR activation 
 
Inspection of the human, mouse and rat VEGFA promoters also revealed several 
potential ATF4 binding sites (Figures 2-5A and A-4).  To determine if any of these sites 
was occupied by ATF4 in response to ER stress, we performed ChIP assays in ATF4 
wild-type (ATF4 wt) and null (ATF4 ko) MEFs.  We were unable to detect binding of 
ATF4 to any of the seven potential sites upstream of the transcription start site in 
response to thapsigargin treatment (data not shown).  However, we did detect 
stress-inducible binding of ATF4 to a site at position +900 relative to the transcription 
start site in the wild-type ATF4 MEFs but not in the ATF4 null MEFs (Figure 2-5B).  
Similar to the wild-type MEFs, we were unable to detect ATF4 binding to any of the five 
upstream regions in the rat promoter (Figure A-6).  However, unlike the human and 
mouse promoter, there does not appear to be a site downstream of the transcription start 
site in the rat promoter that corresponds to the one used in murine cells.  To determine the 
contribution of ATF4 to VEGFA transcription in response to UPR stress inducers, we 
analyzed steady state VEGFA hnRNA (Figure 2-5C) and mRNA (Figure 2-5D) levels in 
ATF4 wild-type and null MEFs.  Although the fold increase in total VEGFA mRNA in  
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Figure 2-5. ATF4 contributes to VEGF expression and binds to the mouse 
promoter in a stress inducible manner. (A) Potential ATF4 sites in the mouse VEGF 
promoter (B) Cross-linked chromatin from ATF4 wild-type or null MEFs that were 
untreated (NT) or thapsigargin-treated (Tg) for 6h was immunoprecipitated with anti-
ATF4 or with a control antiserum (anti-BiP). Precipitated chromatin and input controls 
were used for PCR amplification. (C-D) ATF4 wild-type (black) or null (white) were 
cultured in normal media (NT), thapsigargin-treated (1µM), or tunicamycin-treated 
(2.5µg/ml) for 3 and 6 hours. Total RNA from the indicated samples was subjected to 
qRT-PCR, and VEGF hnRNA (C) or VEGF mRNA (D) levels were determined and 
represented as described above.  Experiments were performed in triplicate (values are 
mean ± SD). 
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response to ER stress was not very dramatic in either the wild-type or null cells, it was 
consistently slightly higher in the ATF4 wt MEFs.  
 
 
ATF6 does not significantly contribute directly to VEGFA expression 
 
Although there were no obvious potential ATF6 binding sites in the human or rat 
VEGFA promoters, there was one potential ATF6 binding site in the mouse VEGFA gene 
at +1.4kb relative to the transcription start site.  Thus, we also examined the potential 
contribution of ATF6 in regulating VEGFA transcription.  qRT-PCR analysis of VEGFA 
mRNA in ATF6 wild-type (ATF6 wt) and null (ATF6 ko) MEFs revealed that ATF6 
does not appear to play a significant role in up-regulating VEGFA expression in response 
to either tunicamycin treatment or incubation in media lacking glucose (Figure 2-6A).  
However, in response to thapsigargin treatment there was a modest, albeit significant, 
increase in total VEGFA mRNA in ATF6 wild-type cells compared to null cells.  The 
difference between the stresses in inducing VEGFA transcripts was a bit puzzling.  
Because XBP-1 transcription is regulated by ATF6 and our analysis revealed that XBP-
1(S) binds to the VEGFA promoter, we examined XBP-1(S) levels in the two lines in 
response to the various UPR inducers.  Western blot analysis revealed a more dramatic 
increase in XBP-1(S) protein levels in the thapsigargin-treated ATF6 wild-type cells 
compared to the null cells (Figure 2-6B), whereas there was no obvious difference 
between the two tunicamycin-treated cell lines.  Somewhat surprisingly, media lacking 
glucose did not induce XBP-1(S) in either cell line.  These data imply that the higher 
levels of VEGFA mRNA observed in the thapsigargin-treated wild-type cells compared to 
the null cells might be partly due to a more robust increase in XBP-1(S) levels in the 
wild-type cells.  
 
 
UPR activation increases VEGFA protein levels 
 
Lastly, we measured the effects of the UPR and hypoxia signaling pathways on 
VEGFA protein levels in the cells (Figure 2-7A) and in the culture supernatant (Figure 
2-7B).  We could readily detect VEGFA in lysates obtained from cells treated with all 
three of the UPR inducers but not in cells cultured in the hypoxia chamber or treated with 
CoCl2 (Figure 2-7A), in spite of the fact that hypoxia increased VEGFA mRNA in this 
cell line to about the same level as tunicamycin treatment.  A faster migrating 
unglycosylated VEGFA was detected in cells treated with tunicamycin and no glucose 
media, as these stressors are known to inhibit protein glycosylation.  In spite of our 
inability to detect VEGFA in hypoxia treated cells, when media from cells treated with 
the various UPR inducers and hypoxia were examined, we readily detected an increase in 
VEGFA secretion with all stressors (Figure 2-7B).  However, the combination of cell-
associated and secreted VEGFA with each of the treatments is not consistent with the 
mRNA levels.  For example, although VEGFA mRNA levels were highest in cells treated 
with thapsigargin compared to any of the other four stress conditions (Figure 2-1A), it 
was not secreted as well from these cells as from tunicamycin or no glucose treated cells.  
Additionally, although both hypoxia and tunicamycin treatment resulted in similar 
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Figure 2-6. ATF6 does not significantly contribute to VEGF expression. (A) ATF6 
wild-type (black) or null (white) MEFs were untreated (NT), thapsigargin treated (1 µM), 
tunicamycin-treated (2.5 µg/ml) or treated with media lacking glucose (No Glu) for 6 
hours. Total RNA from the indicated samples was subjected to qRT-PCR, and the VEGF 
mRNA levels were determined.  (B) XBP-1(S) was detected using western blot analysis 
on cell lysates from ATF6 wild-type and null MEFs that were untreated or treated as 
indicated.  Experiments were performed in triplicate (values are mean ± SD). 
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Figure 2-7. UPR activation increases VEGF protein levels and secretion. (A) C6 
cells were left untreated or treated as indicated for 24 hours. Western blot analyses on cell 
lysates were performed to detect VEGF protein levels.  Hsc70 was used as a loading 
control.  (B) Conditioned media from untreated and treated cells was analyzed for VEGF 
secretion by ELISA.  (C) Total RNA from the indicated samples was subjected to qRT-
PCR, and GRP170 mRNA levels were determined and expressed relative to the control 
cells.  
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increases in VEGFA transcripts, tunicamycin treatment resulted in the secretion of 
greater quantities of VEGFA (Figure 2-7B).  Previous studies demonstrated that the ER 
stress-inducible chaperone GRP170/ORP150 plays an important role in VEGFA 
processing and secretion in the C6 cells [15].  Thus we examined the effects of the 
various stressors on GRP170 induction at both the mRNA and protein levels.  We found 
that tunicamycin and no-glucose were potent inducers of GRP170 mRNA (Figure 2-7C) 
and protein (Figure 2-7A), whereas thapsigargin only modestly induced this chaperone 
and hypoxia had almost no effect on GRP170 levels.  Thus the relatively high levels of 
VEGFA secretion in tunicamycin and no-glucose treated cells are consistent with the 
increased GRP170 levels in these cells.  
 
 
Discussion 
 
Angiogenesis is a normal physiological process that is important for embryonic 
development as well as wound healing [71, 82].  It is carefully controlled by a large 
number of secreted factors that bind to receptors on endothelial cells, as well as negative 
regulators that inhibit angiogenesis through direct effects on endothelial cells or indirect 
effects on growth factor mobilization and activation [70, 82].  Recent studies have shown 
that VEGFA, one of the major proangiogenic factors, is a target of the UPR.  Our 
microarray analysis of UPR targets in thapsigargin-treated Daoy cells confirmed VEGFA 
induction, but unexpectedly revealed that there was a significant up-regulation of 12 
additional positive regulators of angiogenesis, including secreted proangiogenic factors, 
cytokines, and transcription factors that positively regulate proangiogenic factors, as well 
as a decrease in one negative regulator of angiogenesis.  This argues that the regulation of 
angiogenesis is likely to be an important function of the UPR.  Of note, the UPR was a 
potent inducer of IL8 expression in multiple cells lines (Figure 2-2D).  A recent report 
demonstrated that addition of IL8 to endothelial cells can induce VEGFA mRNA and 
protein levels in a HIF1α-independent manner that requires NFκB activation [90]. 
Because ER stress also leads to NFκB activation, it is conceivable that IL8 contributes to 
VEGF induction during UPR activation in some of our lines.  However, although the 
NB1691 cell line potently up-regulates IL8, it does not induce VEGFA mRNA levels on 
UPR activation.  The reason for this is not known as other UPR targets are clearly 
activated in this line and VEGF is induced by hypoxia. 
 
The major function of the UPR is thought to be restoring or maintaining ER 
homeostasis in response to an inadequate or toxic environment that adversely affects this 
organelle and its ability to fold and assemble proteins.  Thus it is perhaps not surprising 
that one mechanism for doing this would be to increase the supply of blood flow to the 
affected cells so that more nutrients and oxygen can be delivered and waste and other 
toxic products could be taken away.  In keeping with this possibility, physiological 
processes like wound healing require increased vascularization [91], and studies show 
evidence of UPR activation in the affected cells [92].  Similarly the placenta must be 
highly vascularized in order to supply adequate quantities of oxygen and nutrients to the 
developing fetus and to remove toxic waste products.  Although there are not data to 
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demonstrate that the UPR is normally activated in the developing trophoblasts, a recent 
report found that Ire1 was required for normal placenta vascularization and fetal  
development [65].  This aspect of the UPR might also be used in pathological conditions 
like cancer [93, 94] and ischemia [95] to stimulate angiogenesis, as in both cases there is 
evidence of UPR activation [52]  
 
We focused our further analysis on VEGFA because it is the best characterized 
and most potent endothelial growth factor that promotes angiogenesis and is a target of 
cancer therapy. Recently a study has shown that VEGFA mRNA can be up-regulated in 
cultured cells by the UPR inducers, thapsigargin and tunicamycin [81].  We confirmed 
the role of the UPR in up-regulating VEGFA expression in various cell lines and also 
shown that the UPR is a much better inducer of VEGFA mRNA than hypoxia in a number 
of transformed and non-transformed cell lines, further arguing that this represents a 
normal function of the UPR.  We next focused our attention on the mechanism of 
increased VEGFA mRNA expression via UPR and hypoxia signaling pathways using the 
C6 rat glioma cell line. The UPR increases VEGFA mRNA stability as well as the 
transcription rate of the gene to an even greater extent than that achieved with hypoxia. 
Several stress-activated protein kinases, including AMPK, have been reported to increase 
VEGFA mRNA stability. The activation of the AMP kinase has been linked to low 
glucose levels that result in diminished ATP production [96].  In addition to nutrient 
deprivation, other metabolic stresses such as hypoxia, oxidative stress and exercise lead 
to activated AMPK [97].  In DU145 prostate carcinoma cells cultured without glucose, 
JNK was shown to act upstream of AMPK pathway to increase VEGFA mRNA stability 
[87].  However, in our analysis of the C6 cells treatment with SP600125 the JNK 
inhibitor had no effect on VEGFA mRNA stability, whereas treatment with the AMPK 
inhibitor enhanced its stability in response to both thapsigargin and no glucose, 
suggesting that conventional UPR inducing agents can also activate AMPK.   
 
Next, we assessed the importance of the major UPR-induced transcription factors 
(i.e., XBP-1(S), ATF4 and ATF6) in mediating VEGFA transcription.  Most recently, 
Ghosh R et al [81], demonstrated that Ire1 null MEFs, which cannot splice XBP-1 and 
induce its downstream targets, have a significant reduction in VEGFA mRNA expression 
compared to the Ire1 wild-type cells when treated with thapsigargin.  Using a 
VEGFA-promoter-luciferase assay and chromatin immunoprecipitation they also showed 
that exogenously supplied XBP-1 can bind to the VEGFA promoter and up-regulate 
VEGFA mRNA expression.  Our studies reveal direct binding of endogenous XBP-1 to 
two distinct sites in the rat VEGFA promoter in response to ER stress.  Our qRT-PCR 
data showed an increase in the VEGFA transcription rate in the XBP-1 wild-type cells 
treated with various UPR inducers compared with the XBP-1 null cells. The increased 
levels of VEGFA mRNA observed in the wild-type cells was primarily due to an increase 
in the transcription rate of the gene, since these inducers had little effect on the stability 
of VEGFA transcript in this cell line (data not shown).  Previously published data showed 
that tumors derived from U87 cells expressing an Ire1 dominant negative construct 
developed smaller tumors with decreased vascularization as compared to tumors from 
control cells [98]. In addition to this study, two independent reports have also 
demonstrated a role for XBP-1 in tumor establishment, growth and angiogenesis [99, 
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100].  However, the former study found that when XBP-1 deficient cells are treated with 
extreme hypoxia/anoxia (pO2 < 0.02 %) in vitro, there is no defect in secretion of the 
proangiogenic factors, VEGFA and bFGF, as compared to wild-type cells.  As these 
extremely low O2 conditions would be expected to induce both the UPR and the HIF 
pathways, it is conceivable that in the absence of XBP-1, HIF1α and 2α are able to 
compensate.  In support of this possibility, there are HIF binding sites in close proximity 
with the XBP-1 “A” site occupied in response to ER stress (Figure 2-4B) in all three 
species.  As tumor cells, ischemic tissue, and wounds are likely to activate both types of 
stress pathways, it will be important to understand the overlap and relative contribution of 
each factor in a physiological setting.   
 
Several studies have demonstrated a role for ATF4 in mediating expression of 
VEGFA in response to various stimuli such as homocysteine [101], arsenite [102], 
oxidized phospholipids [103], and osteopontin [104].  Arsenite is an oxidative stressor 
that stimulates ATF4 binding to the VEGFA promoter in a human retinal pigment 
epithelial cell line at position +1767 relative to the transcription start site [102]. Similar 
observations by another group demonstrated that ATF4 binds to the same AARE site in 
the VEGFA promoter when a human umbilical vein endothelial cell line was stimulated 
with oxidized phospholipids [103].  These results are in accordance with data published 
by Ghosh et al reporting a PERK-ATF4 dependent up-regulation of VEGFA expression.  
Using both PERK and ATF4 null MEFs treated with thapsigargin, they showed that 
VEGFA mRNA levels were decreased as compared to the corresponding wild-type 
MEFs, and demonstrated binding of ectopically expressed ATF4 to the VEGFA promoter 
in cells treated with thapsigargin.  Using ChIP assays, we confirmed that ATF4 
contributes to VEGFA transcription and furthermore demonstrated that endogenous ATF4 
binds to a region ~ +0.9kb downstream of the transcription start site in mouse cells when 
treated with a UPR inducer.  
 
Lastly, our data suggests that ATF6 does not play a significant role in directly 
mediating VEGFA mRNA expression.  We observed a modest increase in VEGFA 
mRNA in the ATF6 wild-type MEFs compared to the ATF6 null cells when treated with 
thapsigargin but not the other stressors.  This induction was most likely due to an increase 
in the XBP-1(S) protein levels observed only in thapsigargin-treated ATF6 wild-type 
cells.  The VEGFA promoter-reporter assay performed by Ghosh et al, showed that 
over-expression of the transcription factor ATF6 increases luciferase activity ~6 fold 
compared to empty vector.  The reporter construct used in this assay was derived by 
inserting ~1kb of the sequence upstream of the mouse VEGFA transcription start site, in 
front of the luciferase gene.  Using two different programs to identify transcription factor 
binding sites in this region of the mouse VEGFA promoter, we were unable to identify 
any potential ATF6 sites.  However, this region contains a potential binding site for 
XBP-1, which this group reported could bind to ectopically expressed XBP-1 using ChIP 
assays.  However, we were unable to detect binding of endogenous XBP-1 to this same 
site (data not shown). 
 
In addition to the role of UPR-inducible transcription factors in mediating VEGFA 
expression, there are data showing that the stress inducible ER chaperone 
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ORP150/GRP170 plays a role in post-translational processing/secretion of VEGFA [15].  
Ectopic expression of ORP150 in C6 cells increased VEGFA secretion, whereas 
decreasing ORP150 levels with an antisense construct resulted in the retention of VEGFA 
in the ER.  Furthermore, tumors arising from the antisense ORP150 C6 glioma 
transfectants demonstrate an initial phase of growth comparable to the wild-type glioma 
cells which was followed by marked regression and decreased angiogenesis within 8 
days.  Our analysis of VEGFA secretion in C6 cells revealed that although hypoxia and 
tunicamycin lead to similar increases in VEGFA mRNA, that more VEGFA was secreted 
from the tunicamycin treated cells, which had higher levels of ORP150/GRP170 mRNA 
and protein levels.  This correlation is further underscored by the finding that although 
thapsigargin was the strongest inducer of VEGFA mRNA, it caused a less robust up-
regulation of GRP170 and less VEGFA was secreted from thapsigargin treated cells than 
from either tunicamycin or no-glucose treated cells.  
 
In conclusion, using microarray analysis we found a significant up-regulation of a 
large proportion of positive regulators of angiogenesis in response to ER stress and 
verified four of these using qRT-PCR assays.  Our studies revealed that in some cell lines 
UPR activation enhanced VEGFA mRNA and protein expression more potently than 
hypoxia and that this was achieved through a combination of transcriptional as well as 
post-transcriptional mechanisms.  Thus, the UPR is likely to be an important regulator of 
angiogenesis in normal physiological settings as well as pathological conditions like 
cancer and ischemia and may synergize with the well-studied HIF pathway activated by 
hypoxia. 
 
 
Materials and Methods 
 
 
Cell culture and stress induction  
 
Daoy human medulloblastoma cell line [105], C6 rat glioma cell line [106], 
XBP-1 wild-type and null MEFs, ATF6 wild-type and null MEFs, and NIH3T3 mouse 
fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum, 2 
mM glutamine and 1% antibiotic-antimycotic at 37ºC in a 5% CO2 incubator. NB1691 
and SKNAS human neuroblastoma cell lines were cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum and 2 mM glutamine. Primary wild-type and ATF4 null 
MEFs were propagated in cell culture as previously described [26].  Cells were plated 
and left untreated (NT) or treated with thapsigargin (Tg, 1 µM), tunicamycin (Tm, 2.5 
µg/ml), homocysteine (HCys, 10 mM), CoCl2 (100 μM), media lacking glucose (No Glu) 
(DMEM cat.no.11966-GIBCO and RPMI cat. no.11879-GIBCO), or cultured in a 
hypoxia chamber containing 1% O2 for the indicated periods of time. 
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mRNA and hnRNA quantification by qRT-PCR 
  
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the 
manufacturer’s protocol. RNA samples were subjected to qRT-PCR, and reactions were 
done in duplicate using a TaqMan One-Step PCR Master Mix kit. Amplification of the 
corresponding genes was achieved using specific primers and probe set and measured 
continuously using an ABI 7900 HTI Detection System. Where indicated, VEGF hnRNA 
was measured using qRT-PCR primers and probe across intron 1 and exon 2, for the rat 
gene and across exon 3 and intron 3, for the mouse gene.  The signal obtained for 
measuring both, mRNA and hnRNA, was compared relative to 18S rRNA internal 
control. A recent study detected down-regulation of ribosomal RNA by ER stress [107]. 
However, in our study the 18S rRNA cycle threshold (Ct) values obtained by qRT-PCR 
remained relatively unchanged in the presence of ER stress arguing that 18S rRNA levels 
were not changing with the conditions used.  The value for untreated cells was set to 1 
and the value for the various treatments was presented as a fraction of this number.  In the 
case of wild-type and null cells, the untreated value for each cell type was set to 1 unless 
otherwise indicated.  
 
 
mRNA stability assay   
 
C6 cells were pre-incubated in normal complete media, media containing 
thapsigargin or no glucose, or in a hypoxia chamber for 6 hours.  Actinomycin D (5 
g/ml- Sigma Aldrich) was added to each test set, and the cells were reincubated for the 
indicated times.  Total RNA was extracted and VEGF mRNA was analyzed by 
qRT-PCR.  
  
 
Chromatin immunoprecipitation  
 
Chromatin immunoprecipitation (ChIP) analysis was performed using a ChIP kit 
(Upstate Biotechnology) according to the manufacturer’s instructions. Briefly, cells were 
incubated for the indicated times with or without different stress inducers.  Formaldehyde 
was then added (final concentration, 1 %), and cells were incubated for 10 minutes at 
room temperature to stabilize DNA-protein interactions.  Cross-linking was stopped by 
the addition of glycine (final concentration, 0.125 M). Cell extracts were sonicated with a 
Branson Sonifier 250 (VWR) for 5 bursts at 10 seconds each at 20 % power output to 
shear DNA to 1kb or less.  Extracts from 107 cells were incubated overnight with 
antibodies against ATF4 generously provided by Dr. David Ron (University of 
Cambridge, U.K.), rabbit anti-XBP-1(S) polyclonal antiserum (Santa Cruz Biotechnology 
sc-7160X) or rabbit anti-BiP polyclonal antiserum [108], which served as a negative 
control. Two percent of the extract volume was removed before immunoprecipitation and 
served as input control. DNA fragments from immunoprecipitated complexes and input 
controls were released by heating at 65ºC overnight and purified using the PCR 
purification kit (QIAquick, Qiagen) according to the manufacturer’s protocol. Purified 
immunoprecipitated DNA and input DNA were then analyzed by PCR.   
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Western blotting  
 
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40, and 0.5 % deoxycholic acid) for 
30 minutes on ice. The proteins were electrophoresed under reducing conditions, 
transferred to a PVDF membrane and probed with the indicated primary antibodies: 
Rabbit anti-XBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were 
purchased from Santa Cruz Biotechnology, mouse anti-HIF1α and mouse anti-BNIP3 
from Abcam, and rabbit anti-phosho-AMP kinase from Cell Signaling. Rabbit anti-CHOP 
has been described previously [56]. Isolation of nuclear and cytosolic fraction for 
detecting HIF1α by Western blotting was performed as previously described [109]. Blots 
were incubated with the appropriate HRP-conjugated secondary antibody, and proteins 
were visualized using the Pierce enhanced chemiluminescent substrate (Thermo 
Scientific).    
 
 
Microarray gene expression analysis  
 
Total RNA (5-10μg) was processed according to the Affymetrix eukaryote 
one-cycle target labeling protocol at the Hartwell center microarray core at St Jude 
Children’s Research Hospital.  Biotin-labeled cRNA (15μg) was hybridized overnight at 
45ºC to the human HG-U133 Plus 2.0 GeneChip array, which interrogates more than 
54,000 human transcripts and ESTs. After staining and washing, arrays were scanned and 
expression values summarized using the MAS5 algorithm as implemented in the GCOS 
v1.4 software (Affymetrix, Santa Clara, CA). Signals were normalized for each array by 
scaling to a 2% trimmed mean of 500. Detection calls (Present, Absent and Marginal) 
were determined using the default parameters of the software. Signal values were 
log2-transformed prior to analysis. Differential expression between thapsigargin-treated 
and untreated cells was determined from two independent experiments using the Local 
Pooled Error t-test(1) (S-Plus 6.2, TIBCO, Palo Alto, CA). False discovery estimates 
were calculated as described [110]. Hierarchical clustering was performed using the 
Spotfire Decision Site 9.0 software (TIBCO). Probe set annotations were obtained from 
the Affymetrix website.  Gene ontology and network analysis was performed using 
Metacore from GeneGo Inc. (St. Joseph, MI).  All data is MIAME compliant, and the raw 
data has been deposited in GEO, a MIAME compliant database, accession number: 
GSE21979. 
 
 
Statistical analysis 
 
All results are expressed as mean values plus or minus SD from triplicate 
measurements performed in 2 to 4 independent experiments producing similar results. 
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CHAPTER 3.    ROLE OF THE UPR AND HIF SIGNALING PATHWAYS IN 
REGULATING VEGF EXPRESSION 
 
 
Introduction 
 
Solid tumors contain regions that are poorly oxygenated due to a limited 
accessibility to functional blood supply.  These areas are extremely heterogenous and 
very dynamic in an individual tumor and between tumors in a given patient. Hypoxia is 
an important factor that determines prognosis for patients, because it has the ability to 
alter the cellular metabolism and cause resistance to radiotherapy and chemotherapy. 
Hypoxic cells are more resistant to radiation therapy compared to well-oxygenated cells, 
because oxygen is required for the induction of DNA damage by radiation [111]. The 
poorly vascularized, hypoxic regions of the tumor are also resistant to chemotherapeutic 
agents due to inefficient drug delivery by distantly located blood vessels. Clinical 
evidence suggests that hypoxia not only alters the therapeutic outcome of the patient but 
also contributes to a more aggressive tumor phenotype. The use of mouse models in 
tumor biology has enabled us to understand some important aspects of tumor 
oxygenation. First, the severity of hypoxia can vary from completely anoxic (extreme 
hypoxia) to mildly hypoxic or even normoxic regions in the tumor. The variations 
observed in the pO2 in different regions of the tumor is largely due to the transient 
changes in blood flow and the inability of blood vessels to fuel the rapidly expanding 
tumor mass. Second, the oxygenation status of any tumor cell is highly dynamic due to 
the disorganized architecture of tumor blood vessels and rapid vasoconstriction and 
dilation of the vasculature. These patterns of oxygenation have very different biological 
and clinical implications, as varying amounts of oxygen levels in the cell have the ability 
to activate cytoprotective stress signaling pathways [112, 113].  
 
The normal atmospheric concentration of oxygen (normoxia) is 21 % or 160 mm 
Hg. Measurements of oxygen levels in animal models have demonstrated that the pO2 in 
regions of the tumor at a distance of greater than 100 μm from a vessel can vary from 10 
mm Hg (hypoxia) to nearly 0 mm Hg (anoxia). Studies with cultured cells have revealed 
that when oxygen levels drop below 5% O2 or 38 mm Hg, the hypoxia-inducible factor 
(HIF) pathway is activated [114]. Transcriptional responses to hypoxia are largely 
regulated by HIF, a heterodimeric protein composed of an oxygen-labile  subunit and a 
constitutively expressed  subunit.  There are two  subunit members, HIF1 and 
HIF2, which are continuously synthesized and rapidly degraded under normal 
physiological conditions [115]. The oxygen-dependent degradation of the HIF--subunit 
is mediated by hydroxylation of proline 402 and proline 564 by prolyl hydroxylase 
domain protein 2. Hydroxylated HIF- binds to von Hippel Lindau tumor suppressor 
protein (VHL), which then targets the α subunit for degradation via the 26S proteasome 
[10]. The decrease in oxygen levels that occurs with increasing distance from a blood 
vessel also correlates with a decrease in the environmental pH.  The decreased pH 
observed in tumor tissues is due to an increase in the glycolytic rate of cancer cells. As 
cancer cells shift their metabolism to glycolysis from oxidative phosphorylation, due to 
the decreased availability of oxygen, there is an increase in the production of lactate, 
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which is secreted into the extracellular space making the tumor microenvironment more 
acidic [116]. 
 
Several more recent studies have demonstrated that extreme hypoxia (<0.02 % 
O2) can also activate the UPR [117, 118], which enables the cell to adapt to the 
suboptimal conditions for protein folding by decreasing the overall rate of protein 
synthesis. Secreted and membrane proteins are processed in the endoplasmic reticulum 
where they encounter molecular chaperones and folding enzymes, like protein disulfide 
isomerases, that catalyze the formation of disulphide bonds.  These bonds serve to 
stabilize both folding intermediates and the mature protein, but the enzymatic reaction 
that catalyzes their formation requires molecular oxygen. Hence, limiting amounts of 
oxygen in the cell can impinge on the protein folding capacity in the ER, leading to the 
accumulation of unfolded proteins and activation of the UPR [16]. The change in the pH 
of the tumor microenvironment that occurs in response to the shift to glycolytic 
metabolism also has the ability to contribute to UPR activation.  The reduced pH can 
change the net charge on the side chains of amino acids, which play a major role in 
defining folding pathways. The high metabolic rate of many tumor cells put additional 
demands on the folding capacity of the ER and provides yet another stimulus for UPR 
activation.  Thus, within a tumor mass it is likely that individual cells are likely to have 
different compliments of these two stress signaling pathways, with some cells having 
only one of them activated and others having both. 
  
 The HIF pathway is well documented to play a significant role in the production 
of VEGF in cultured cells and in promoting angiogenesis in animal models. VEGF is a 
potent proangiogenic factor required for proliferation and migration of endothelial cells 
that enables formation of new blood vessels. In vivo studies reported that HIF1-/- 
embryonic stem cell derived tumors had fewer blood vessels and impaired vasculature 
within the tumor mass as compared to the control wild-type counterparts [119]. The 
importance of the hypoxia-inducible transcription factors, HIF1 and HIF2, in 
regulating VEGF expression was further emphasized from complete knockout 
experiments. Both, HIF1 and HIF2 knockout animals are embryonic lethal due to lack 
of functional vasculature [119, 120].   More recently, we [49], and others [121], have 
shown that the UPR also plays an important role in regulating VEGF expression at both 
transcriptional and post-transcriptional levels in cultured cells.  While we wish to 
ultimately assess the contribution of the UPR to tumor angiogenesis, due to the 
heterogeneous nature of tumors, it is critical that we first understand the relative 
contribution of the UPR and HIF signaling pathways when experienced alone and in 
combination, in regulating VEGF expression using carefully defined conditions that are 
specific to each of these stress pathways.  
 
 Due to the large variety of knockout lines available, in our previous study we used 
a combination of rodent cell lines to identify critical elements of the UPR.  We 
demonstrated that both XBP-1(S) and ATF4 bound to the VEGF promoter and 
contributed to VEGF expression. However, the exact contribution of these two factors 
could not be determined, because the corresponding controls for the various mouse 
knockout cell lines had different basal and stress induced levels of VEGF mRNA and 
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protein. To remedy this problem and to determine the significance of the UPR in 
regulating VEGF expression in human tumor cell lines, we identified two human 
neuroblastoma cell lines, SKNAS and NB1691, which have low basal levels of VEGF 
expression that are significantly induced by ER stress.  Similar to the studies in rodent 
cells, we were able to detect both XBP-1(S) and ATF4 bound to the human VEGFA 
promoter in a stress-inducible manner. Using siRNA in transient expression experiments, 
we reduced the expression of both XBP-1(S) and ATF4 independently and found that 
ATF4 plays the predominant role in regulating VEGF expression in response to UPR 
activation in human cells.  Thus, we have engineered these two neuroblastoma lines to 
inducibly express shRNA to ATF4.  In addition, clones that stably express shRNA to 
HIF1α have been obtained for both cell lines.  In preliminary experiments, we found that 
there is a synergy between the two pathways, as VEGF expression is significantly higher 
when cells are exposed to both stresses simultaneously.  However, although ATF4 plays 
a major role in regulating VEGF expression in cells experiencing only ER stress, it does 
not contribute significantly to its expression when the UPR and HIF pathways are 
activated together in cell culture experiments. Instead, the UPR appears to enhance 
HIF1 activity and result in HIF1-dependent increases in the expression of VEGF and 
other HIF targets via an as yet undetermined mechanism. The neuroblastoma cell lines 
expressing inducible stable ATF4 shRNA will be useful in animal experiments to 
determine the contribution of this factor at various time points during the course of tumor 
development.  
 
 
Results 
 
 
Defining culture conditions that are specific to HIF and UPR pathways 
 
To determine the contribution of the UPR versus the HIF pathway in regulating 
VEGF expression in human neuroblastoma cell lines, it was critical to identify conditions 
that would activate each pathway without affecting the other.  This was particularly 
important, since extreme hypoxia has been reported to activate not only the HIF pathway 
but also the UPR [117, 122]. In addition, we wished to use more physiological activators 
of the UPR instead of the more traditional pharmacological activators, like thapsigargin 
or tunicamycin.  SKNAS and NB1691 human neuroblastoma cells were treated with 
media containing decreased concentrations of glucose to mimic a physiological stress 
experienced by tumors. Under non-stressed conditions, regular tissue culture media 
contains 25 mM glucose. A variety of concentrations were tested, but we chose 1 mM, a 
concentration that readily activated the UPR, was not toxic to cells, and is likely to mimic 
conditions encountered by tumor cells [123].  The two lines were treated with low 
glucose for 8 and 16 h and the effects on UPR targets and HIF targets were assessed by 
real-time PCR.  The cell lines were also incubated in a hypoxia chamber containing 1% 
O2 to activate the HIF signaling pathway. In both cells lines, low glucose lead to the up-
regulation of GADD34, a transcriptional target of ATF4 that is activated downstream of 
PERK (Figure 3-1A and C), whereas incubating the cells in 1% O2 had no affect on this  
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Figure 3-1. Low glucose activates the UPR but not the HIF signaling pathway and 
1% O2 (hypoxia) activates the HIF pathway but not the UPR.  Cells were either left 
untreated (NT), incubated in media containing 1 mM glucose (Lglu), or treated in a 
hypoxia chamber containing 1% O2 for 8 hours and 16 hours as indicated. Total RNA 
from the indicated samples was subjected to qRT-PCR to quantify Gadd34 mRNA 
(A{SKNASluc} and C{NB1691luc}) or BNIP3 mRNA (B{SKNASluc} and 
D{NB1691luc}) at the indicated time points.  RNA levels were expressed relative to the 
control untreated samples for each line, which was set to 1. Experiments were performed 
in duplicate (values are mean ± SD). 
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target. Similarly, when the cells were cultured in 1% O2, the HIF target, BNIP3, was 
readily induced, but there was no up-regulation of the UPR target, GADD34 (Figure  
3-1B and D). Thus, it was possible to define conditions that were specific for each of the 
two stresses. 
 
 
UPR and HIF activation induces VEGF secretion 
 
We next measured the effect of these pathways on VEGF secretion using the 
stress conditions described above that activated either the HIF or UPR alone without 
affecting the other pathway.  Although there was a detectable amount of VEGF secreted 
from untreated cells, we observed an increase of VEGFA in the media from cells treated 
with either of the stress inducers (Figure 3-2). Culturing cells in low glucose media for 16 
hours caused a 3-fold increase in VEGF secretion as compared to the untreated control 
sample in the SKNASluc line. Hypoxia seemed to be a somewhat more potent inducer of 
VEGF secretion in this line, as 16 hours of treatment in the hypoxia chamber resulted in a 
~5-fold increase as compared to the control sample. When the cells were treated with a 
combination of both stresses; hypoxia and low glucose media, we observed an increase in 
VEGF secretion that was somewhat greater than what was seen with either of the stress 
conditions alone (Figure 3-2). 
 
 
UPR and HIF signaling pathways have a synergist effect on VEGF transcription 
 
Since both pathways are known to regulate VEGF at the transcriptional level, we 
determined the relative contribution of the UPR and HIF signaling pathways in regulating 
both the transcription rate and steady state mRNA levels. VEGF hnRNA levels were used 
as a measure of the transcription rate of the gene. The VEGF transcription rate was 
increased 3-fold in SKNASluc cells treated with low glucose media for 8 hours, which 
was increased further after 16 hours (Figure 3-3A). Hypoxia induces VEGF transcription 
rate 4 fold at both, 8 and 16-hour time points. The combination of both UPR and HIF 
activation results in an increase in VEGF hnRNA levels to 7-fold at 8 hours, and after 
16 hours the combination of these two stress pathways appeared synergistic and induced 
the VEGF transcription rate 12-fold. The VEGF mRNA levels were induced 2 fold in 
SKNASluc cell line after 8 and 16 hours of treatment in media lacking glucose (Figure 
3-3B). In keeping with the increased transcription rate observed with the combination of 
UPR and HIF activation, we found an additive effect on up-regulation of VEGF mRNA 
levels in the line at both time points. The NB1691luc cell line had a similar pattern of 
VEGF hnRNA and mRNA induction with UPR and HIF activation at both time points. 
VEGF expression was induced 4 fold with each of these pathways activated alone at 
both time points as indicated in Figure 3-2C and D. However, the combination of both 
stresses had a more potent and synergistic effect on up-regulating VEGF expression, 
particularly in the NB1691 cell line.  
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Figure 3-2. VEGF secretion is increased with UPR and HIF activation.  
SKNASluc cells were either left untreated (NT), incubated in media containing 1 mM 
glucose (Low Glu), treated in a hypoxia chamber containing 1% O2 (Hypoxia 1% O2) or 
treated with a combination of low glucose media and incubated in a hypoxia chamber 
(Low Glu 1 mM+Hypoxia 1% O2) for 8 hours and 16 hours as indicated in the figure. 
Conditioned media was collected from the indicated samples at the given time points and 
analyzed for VEGF secretion by ELISA.  Experiments were performed in duplicate 
(values are mean ± SD). 
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Figure 3-3. VEGF mRNA and hnRNA levels are up-regulated with the UPR and 
HIF signaling pathways alone and more potently with the combination of both 
stresses together.  Cells were either left untreated (NT), incubated in media containing 1 
mM glucose (Low Glu), treated in a hypoxia chamber containing 1% O2 (Hypoxia 1% 
O2) or treated with a combination of low glucose media (1 mM) and incubated in a 
hypoxia chamber (Low Glu 1 mM+Hypoxia 1% O2) for 8 hours and 16 hours as 
indicated in the figure. Total RNA from the indicated samples was subjected to qRT-PCR 
to quantify VEGF hnRNA (A {SKNASluc} and C {NB1691luc}) or VEGF mRNA 
(B{SKNASluc} and D{NB1691luc}) at the indicated time points.  RNA levels were 
expressed relative to the control untreated samples for each line, which was set to 1. 
Experiments were performed in duplicate (values are mean ± SD). 
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Human VEGF promoter has potential binding sites for both UPR-inducible and 
HIF transcription factors 
 
We next analyzed 10kb upstream and 3 kb downstream of the transcription start 
site of the human VEGF promoter for potential binding sites of UPR-inducible 
transcription factors, XBP-1(S) and ATF4 and hypoxia-inducible HIF. A number of 
potential binding sites were identified for each of these factors as illustrated in Figure 
3-4. Under hypoxic conditions, HIF1α rapidly accumulates, dimerizes with HIF1β, and 
binds to the core DNA binding sequence 5’-RCGTG-3’ (R, purine (A or G)) on target 
genes. On the other hand, upon UPR activation XBP-1(U) is spliced to form the activated 
form; XBP-1(S), which translocates to the nucleus and binds to core DNA sequence 
5’-ACGTG-3’. Upon UPR activation, ATF4 is translated and binds to its target genes 
containing the core 5’-CGTXA-3’ (X= C or A) sequence. Inspection of the human VEGF 
promoter indicated that several of the potential UPR-inducible transcription factor sites 
overlapped with possible HIF binding sites. Thus, we first tested occupation of these sites 
when each pathway was activated alone. 
 
 
ATF4 and XBP-1 bind to the human VEGF promoter in response to UPR activation 
and HIF1α binds in response to hypoxia 
 
To determine if either of the UPR induced transcription factors binds to the 
human VEGFA promoter in response to ER stress, we performed ChIP assays in the 
SKNAS, NB15 and NB7 cell lines.  We were unable to detect binding of ATF4 to any of 
the six potential sites upstream of the transcription start site in response to low glucose 
treatment (data not shown).  However, we did detect UPR-stress-inducible binding of 
ATF4 to a site at position +1.2 kb relative to the transcription start site (Figure 3-5D), 
which is analogous to where ATF4 binds in the mouse promoter. We also performed 
ChIP assays in the human neuroblastoma cell lines, NB7 and NB15, and were able to 
detect binding of XBP-1(S) at a region 0.5 kb upstream of the transcription start site after 
treatment with the UPR inducer, thapsigargin (Figure 3-5E).  Promoter analysis of the 
human VEGFA gene revealed several potential HIF binding sites (Figure 3-5C).  It has 
been reported in the literature that HIF1α binds to the human VEGF promoter -900 bp 
relative to the transcription start site in response to hypoxia [8]. We performed ChIP 
assays in the SKNAS cell line to determine if this site and the other potential HIF binding 
sites are occupied with hypoxia (1% O2).  We detected a slight but reproducible binding 
of HIF1α to a region on the human VEGF promoter -900bp relative to the transcription 
start site in response to hypoxia (Figure 3-5F), but were unable to detect HIF1α to any of 
the other potential binding sites on the promoter. 
 
 
ATF4 plays a major role in regulating UPR-induced VEGF secretion in SKNASluc 
cells 
 
Chromatin immunoprecipitation studies performed in the human neuroblastoma 
cell lines demonstrated that ATF4 and XBP-1(S) bind to the human VEGF gene on UPR  
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Figure 3-4. Potential binding sites for XBP-1, ATF4 and HIF1 on the human 
VEGF promoter. Potential binding sites of UPR downstream transcription factors in 
human VEGF promoter. The online software rVista was used to identify potential 
binding sequences of transcription factors, XBP-1 (cyan), ATF4 (green) and HIF (red) in 
a region 10 kb upstream and 3 kb downstream of the transcription start site (TSS) on the 
human VEGFA promoter. 
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Figure 3-5. UPR-inducible transcription factors, ATF4 and XBP-1(S) bind to the 
human VEGF promoter in response to UPR activation and HIF1α binds in response 
to hypoxia. Potential ATF4 (A), XBP-1(S) (B) and HIF (C) sites in the human VEGF 
promoter.  Cross-linked chromatin from SKNAS cells that were untreated (NT), 
incubated in media containing 1 mM glucose (Lglu) or treated in a hypoxia chamber 
containing 1% O2 for 8hours were immunoprecipitated with anti-ATF4 (D) or anti-HIF1α 
(F). Human neuroblastoma cell lines, NB7 and NB15 either left untreated or treated with 
thapsigargin, were used in ChIP assays with anti-XBP-1(S) antibody (E). Immuno-
precipitated chromatin and input controls were used for PCR amplification. 
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activation. Our previous study revealed that ATF4 also binds to the mouse VEGF gene 
using mouse embryonic fibroblasts deficient in this factor. XBP-1(S) was also shown to 
bind to the rat VEGF promoter and using knockout cell lines, and we were able to show 
that it plays a role in regulating VEGF expression in cell culture experiments. We were 
unable to determine the exact contribution of ATF4 and XBP-1 in regulating VEGF 
expression as the untreated wild-type MEFs had different basal levels of VEGF and 
induced its expression to different levels [49]. To overcome this problem, we performed 
transient siRNA experiments to determine the contribution of these two UPR 
transcription factors in the same human cell line. Since it is important to obtain 100% of 
the cell population expressing the siRNA, we co-transfected the indicated siRNAs with 
FITC-labeled non-targeting RNA and then sorted the samples after 48 hours of 
transfection to obtain only the viable FITC positive cells. Cells transfected with siRNA 
targeting human ATF4 significantly decreased UPR-induced expression of this factor and 
had no significant effect on XBP-1(S) protein levels (Figure 3-6B). In a similar manner, 
cells transfected with XBP-1(S) siRNA had significantly decreased expression of 
UPR-induced XBP-1(S) protein. Of note, hypoxia (1% O2) did not induce either ATF4 or 
XBP-1(S) protein levels (Figure 3-6 B). The culture supernatant from each group was 
obtained and used to measure VEGF protein levels by ELISA. VEGF secretion was 
measured from the negative control cells, as well as cells treated with ATF4 siRNA or 
XBP-1(S) siRNA. Knocking down ATF4 expression significantly reduced VEGF 
secretion to the basal level, where as knocking down XBP-1(S) only decreased VEGF 
secretion 25% as compared to the negative control-thapsigargin treated sample. These  
results suggest that ATF4 is the major regulator for UPR-induced VEGF secretion in the 
SKNASluc cell line.  
  
 
Inducible stable knockdown of ATF4 inhibits VEGF transcription rate in response 
to low glucose but not hypoxia or the combination 
 
To further test the role of the UPR-inducible transcription factor, ATF4, in 
regulating VEGF expression, we engineered doxycycline-inducible knockdown 
SKNASluc lines, and are in the midst of selecting clones for the NB1691 cell line. This 
strategy will enable us in the future to manipulate the expression of ATF4 in xenograft 
studies at various time points during the course of tumor growth. Single cell clones were 
isolated after transfecting with a single shRNA specific for ATF4.  The cells were 
incubated with dox for 0, 24, 48hr and then treated with thapsigargin for 16 hours.  Cell 
lysates were prepared and blotted for ATF4 to examine the effects of the shRNA on 
ATF4 expression.  We also examined cell lysates for XBP-1 expression as a negative 
control.  Two representative clones were isolated that showed a significant inhibition of 
stress-induced ATF4 expression and decreased Gadd34 mRNA levels-a downstream 
target of ATF4 (Figure 3-7A and B). When these clones were then examined for the 
effects on UPR-induced VEGF transcription, we found that the rates were reduced to 
basal levels. As anticipated, decreasing ATF4 expression had no effect in regulating 
hypoxia-induced VEGF expression, keeping with the results obtained from the transient 
knockdown experiments.  Although we started isolating clones with inducible 
XBP-1shRNA expression, given the fact that decreasing ATF4 appeared to block the  
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Figure 3-6. ATF4 plays an important role in regulating VEGF secretion in 
response to UPR activation. SKNASluc cells were either transiently co-transfected with 
FITC-labeled non-targeting RNA and siRNA specific for human XBP-1(S) or ATF4 as 
indicated in the figure. As a control, cells were transfected with only FITC-labeled 
non-targeting RNA. After 48hours, cells were sorted and the FITC positive viable 
population was re-plated. 24 hours post-sorting, the cells from each group were either left 
untreated, treated with 1μM thapsigargin or incubated in a hypoxia chamber (1% O2). (A) 
Conditioned media was obtained from each treatment as indicated in the figure and 
analyzed for VEGF secretion by ELISA. (B) Western blot analysis was performed on cell 
lysates as indicated in the figure. ATF4 and XBP-1(S) levels were analyzed from nuclear 
fractions and Lamin-B1 was used as a loading control. 
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Figure 3-7. ATF4 regulates UPR-induced VEGF transcription rate but has no 
affect in response to hypoxia or the combination of both the pathways. Two clones 
with stable expression of Tet-repressor and pSuperior.puro-ATF4shRNA vectors in the 
SKNASluc cell line were obtained. (A) The ATF4shRNA clones were treated with 
doxycycline (1μg/ml media) for 24 hours or 48 hours after which the cells were either left 
untreated or treated with thapsigargin for 16 hours. Cells were harvested and ATF4 
protein levels were measured using western blot analysis. (B) The negative control cell 
line and ATFshRNA clones were treated with Dox for 48 hours following which they 
were either left untreated or treated as indicated in the figure for 16 hours. Cells were 
harvested and RNA was extracted to measure Gadd34 levels- a downstream target of 
ATF4. (C) The negative control cell line and ATFshRNA clones were treated with Dox 
for 48 hours following which they were either left untreated or treated with low glucose 
media (1 mM glucose), incubated in a hypoxia chamber (1% O2) or treated with a 
combination of low glucose media and hypoxia for 16 hours. Post-treatment cells were 
harvested, RNA was extracted and total RNA from the indicated samples was subjected 
to qRT-PCR to quantify VEGF hnRNA.  RNA levels were expressed relative to the 
control untreated sample, which was set to 1. 
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UPR-induced expression of VEGF completely, we did not continue with these. 
 
We next designed an experiment to determine the relative contribution of ATF4 to 
VEGF expression when cells have activated both the UPR and HIF pathways 
simultaneously.  To our surprise, we found that decreasing ATF4 expression had no 
perceivable effect in regulating VEGF transcription rate when both, the HIF and UPR 
signaling pathways were activated together (Figure 3-7C).  
 
Thus, we first examined ATF4 levels in these clones and assessed the binding 
ability of this factor in the presence low glucose or both stresses together. As observed in 
the parental line, ATF4 binds to the human VEGF promoter 1.2 kb downstream of the 
transcription start site when treated with low glucose media (Figure 3-8B). A somewhat 
fainter PCR product for ATF4 binding was detected with a combination of both stresses 
together. We also analyzed ATF4 protein levels in the SKNASluc (Figure 3-8C) and 
NB1691 (Figure 3-8D) by Western blot analyses. ATF4 protein levels were induced both 
with low glucose media, which activates the UPR, as well as with a combination of low 
glucose media and hypoxia in both cell lines. However, it must be noted that ATF4 
protein levels were decreased in both lines when the two pathways are activated together 
as compared to UPR activation alone, particularly at later time points. The ChIP assay 
was performed after 8 hours of treatment as indicated in the figure, and at this time point 
ATF4 levels appear to be more similar when either the UPR is activated alone or in 
combination with hypoxia (Figure 3-8C). 
 
 
HIF1α binding to the human VEGF promoter appears greater with the combination 
of hypoxia and low glucose 
 
We repeated ChIP assays in the SKNASluc to determine if this site and the other 
potential HIF binding sites are occupied with hypoxia alone and the combination of 
hypoxia and low glucose together.  We detected hypoxia-inducible binding of HIF1α to 
the region on the human VEGF promoter -900bp relative to the transcription start site 
(Figure 3-9B). We were also able to detect binding of HIF1α with the combination of 
hypoxia and low glucose, which appeared to be somewhat stronger, although this has not 
been repeated using quantitative PCR analysis, which we will do in our follow-up 
studies. We also analyzed HIF1α protein levels in the SKNASluc (Figure 3-9C) by 
Western blot analyses. HIF1α protein levels were induced with hypoxia, however, unlike 
ATF4, the combination of low glucose media and hypoxia reproducibly lead to somewhat 
similar levels of HIF1α.  
 
 
HIF1α regulates VEGF transcription rate in response to hypoxia and the 
combination of both stresses together 
 
Our ATF4 knockdown experiments argued that ATF4 did not appear to contribute 
to VEGF expression with the combination of low glucose and hypoxia.  This could 
suggest that another UPR-induced transcription factor played a bigger role with the  
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Figure 3-8. UPR-inducible transcription factor, ATF4, binds to the human VEGF 
promoter. (A) Potential ATF4 sites in the human VEGF promoter. (B) Cross-linked 
chromatin from SKNASluc cells that were untreated (NT), incubated in media containing 
1 mM glucose (Lglu), treated in a hypoxia chamber containing 1% O2 or treated with a 
combination of low glucose media and incubated in a hypoxia chamber (Hyp+Lglu) for 
8hours were immunoprecipitated with anti-ATF4. Immuno-precipitated chromatin and 
input controls were used for PCR amplification. As a positive control, primers spanning 
the ATF4 binding region on the CHOP promoter were used to PCR amplify the anti-
ATF4 precipitated chromatin. ATF4 protein levels were detected in SKNASluc (C) and 
NB1691luc (D) cells treated with low glucose (1 mM), hypoxia or Low glucose + 
Hypoxia using Western blot analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
  51
 
 
 
Figure 3-9. HIF1α binds to the VEGF human promoter when the HIF signaling 
pathway is activated alone and in combination with the UPR.  (A) Potential HIF sites 
in the human VEGF promoter. (B) Cross-linked chromatin from SKNASluc cells that 
were untreated (NT), incubated in media containing 1 mM glucose (Lglu), treated in a 
hypoxia chamber containing 1%O2 or treated with a combination of low glucose media 
and incubated in a hypoxia chamber (Hyp+Lglu) for 8 hours were immunoprecipitated 
with anti-HIF1α. Immuno-precipitated chromatin and input controls were used for PCR 
amplification. (C) HIF1α protein levels were detected in SKNAS cells treated with Hyp 
and Hyp+Lglu using Western blot analysis.  
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combination of stresses.  Thus, we first wished to determine the contribution of HIF1α in 
regulating VEGF transcription rate.  To do so, we analyzed SKNAS cells that have stable 
expression of HIF1α shRNA. As anticipated, the VEGF transcription rate was decreased 
to basal levels in the cells expressing HIF1α shRNA were incubated in a hypoxia 
chamber compared to the control line, whereas there was no effect on UPR induced 
expression. However, we found that the VEGF transcription rate was reduced to near 
basal levels in the HIF1α shRNA cells when they were treated with the combination of 
hypoxia and low glucose as compared to the negative control (Figure 3-10A). This 
argued that instead of both stress-regulated transcription factors playing a joint role in 
increasing VEGF transcription that the UPR was somehow increasing either HIF 
expression or activity. 
 
As this had not been reported previously to our knowledge, we wished to 
determine how the UPR was affecting HIF.  Although HIF is not induced at the 
transcriptional level in response to hypoxia, we reasoned that if the UPR either led to 
increased HIF mRNA by either increasing its transcription or stability, that there might be 
a larger pool of HIF protein to be stabilized by ER stress. Therefore, we first measured 
HIF transcription rate with both stresses alone and the combination. Although HIF 
transcription rate was not induced with hypoxia alone at either of the time points we 
analyzed, there was a modest (~2 fold) but reproducible increase in the HIF transcription 
rate when both stress pathways were activated together (Figure 3-10B). These results 
suggest that the UPR might synergize with the HIF pathway by up-regulating HIF1α 
transcription.  Further studies in other lines and at addition time points will be required to 
determine if indeed HIF1α is a transcriptional target of the UPR. 
 
 
Lactate production is inhibited in SKNASluc cells treated with low glucose and the 
combination of low glucose + hypoxia 
 
A second possibility for the observed synergy relates to the mechanism used by 
tumor cells to produce energy. Due in part to limited availability of oxygen, cancer cells 
generate ATP through a less efficient mechanism compared to normal differentiated cells 
by increasing glycolysis and decreasing oxidative phosphorylation.  This switch in 
metabolism is known as the Warburg effect. By decreasing glucose, which is necessary 
for glycolytic energy production, we reasoned that perhaps when oxygen levels were also 
limited in our experimental set up, it was possible that the cells would be forced to 
continue using oxidative phosphorylation and thus become more hypoxic then when 
similar levels of oxygen were encountered alone, which could result in more HIF activity. 
As a somewhat indirect method of testing the possibility that the combination of these 
stresses could increase the hypoxic state of the interior of the cells, we measured lactate 
production from the SKNASluc treated with various UPR inducers, with hypoxia alone, 
and with the combination (Figure 3-11). Lactate secretion gives us a measure of the 
amount of glycolysis occurring in the cell, because glucose is broken down via multiple 
steps to pyruvate and finally converted to lactate as the end product. We observed a 
relatively high basal level of lactate secretion in the untreated cells, suggesting that they 
were already using some glycolysis to produce energy. This is a common feature of  
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Figure 3-10.   HIF1α regulates VEGF transcription rate in response to HIF 
signaling and the combination of UPR and HIF signaling.  (A) SKNAS cells that have 
stable expression of either HIF1α shRNA or control shRNA were either left untreated 
(NT), incubated in media containing 1 mM glucose (Low Glu), treated in a hypoxia 
chamber containing 1% O2 (Hyp) or treated with a combination of low glucose media (1 
mM) and incubated in a hypoxia chamber (Hyp+Lglu) for 8 hours as indicated in the 
figure. Total RNA from the indicated samples was subjected to qRT-PCR to quantify 
VEGF hnRNA.  RNA levels were expressed relative to the control untreated samples for 
each line, which was set to 1. (B) SKNASluc cells were treated with low glucose media, 
hypoxia and the combination of both stresses for 8 and 16 hours as indicated in the 
figure. Total RNA was extracted and subjected to qRT-PCR to quantify HIFhnRNA 
levels. 
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Figure 3-11.   Lactate production from SKNASluc cells treated with UPR inducers 
and hypoxia. SKNASluc cells were either left untreated or treated with thapsigargin 
(Tg1 μM), low glucose media (1 mM), hypoxia (1% O2) or a combination of Tg and 
hypoxia or Low glucose media and hypoxia for various time points as indicated in the 
figure. Post-treatment cells were harvested, media was collected, de-proteinized using a 
10 kD spin column and used to measure lactate production. Lactate is represented as 
mmol secreted per 1x106 cells. 
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cancer cells. As anticipated, lowering the glucose levels resulted in decreased secretion of 
lactate at all times points, whereas treating cells with thapsigargin, another UPR inducer 
which was not expected to affect cellular glucose levels, had no effect on lactate 
production.  Although we anticipated that incubating cells in hypoxia would increase 
lactate production, we observed only a modest increase at the latest time point in our 
experiment.  Two interesting observations did come from this experiment.  First, in all 
cases, treating the cells with low glucose simultaneous with low oxygen, radically 
decreased the production of lactate, indicating that indeed glycolysis was not possible 
without sufficient availability of glucose.  Thus it is likely that the cells are more reliant 
on oxygen for energy production and might become more hypoxic at a given 
concentration of oxygen or at an earlier time after switching to low oxygen conditions.  A 
second interesting result was found with cells that were subjected to the combination of 
thapsigargin and hypoxia.  As expected, in this case there was no effect of the UPR on 
lactate production.  Based on this hypothesis, we would not have expected a synergy with 
thapsigargin and hypoxia on VEGF production.  However, inspection of VEGF 
transcription rates with this combination of stresses reveal higher levels of VEGF 
induction than with either stress alone (data not shown). 
 
 
Discussion 
 
A limiting microenvironment can activate cellular stress pathways like the UPR 
and HIF signaling when nutrients and oxygen levels are suboptimal. These pathways 
synergize to positively regulate proangiogenic factors, which stimulate growth of new 
blood vessels toward the affected cells to restore homeostasis. Our tissue culture studies 
revealed that the UPR and HIF signaling pathways induce VEGF expression to a greater 
extent than each of the stress pathways alone. In the case of a rapidly proliferating tumor 
mass, there should be a subpopulation of tumor cells that activate both stress pathways 
together, which would result in greater secretion of VEGF as compared to tumor cells 
that have only one pathway activated. The mechanism for this synergy in the case of a 
pharmacological UPR activator like thapsigargin is unknown, although in the case of low 
glucose our data allows us to speculate. Tumor cells have an altered metabolism that 
enables them to produce significant amounts of ATP from glycolysis rather than 
oxidative phosphorylation.  By decreasing the oxygen supply to a cell we would expect to 
see a further increase in its glycolytic potential. The synergistic induction in VEGF 
expression when observed when both stresses were present together led us to speculate 
that when glucose was limited the cell would be forced to rely more on oxidative 
phosphorylation, which might further decrease cellular oxygen levels and result in more 
hypoxic conditions in the cell for a given concentration of oxygen.  Indeed, we found that 
the levels of glucose in our “low glucose” conditions was not sufficient to support 
glycolysis as a means of energy production.  This would imply that the cells were either 
producing less ATP or producing it via oxidative phosphorylation.  To distinguish 
between these possiblities, it would be necessary to measure cellular ATP levels or 
oxygen consumption by the mitochondria, as this is where oxidative phosphorylation 
takes place.  If the synergy on VEGF transcription that we observed with low glucose and 
hypoxia was due to increasing the intracellular level of hypoxia, we would not have 
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expected to see a synergy when thapsigargin was used to activate the UPR with hypoxia, 
since this did not reduce lactate production.  However, we also found that VEGF mRNA 
levels were significantly higher when these two activators were combined. Thus, there 
must be another mechanism for synergy between these responses. It is formally possible 
that in this case ATF4 still binds to the VEGF promoter to increase transcription.  
Experiments with this combination of stresses will be conducted in the ATF4 deficient 
cells.  Importantly, these data have been obtained with a single line and must be 
reproduced in another line before we can draw conclusions.  However, if they hold, these 
results have very important implications in tumor angiogenesis, as they might argue 
against a need to target the UPR pathway to inhibit VEGF production in cells where both 
stress pathways are activated due to both limited oxygen and glucose. 
 
The importance of HIF1 in regulating VEGF expression is well documented in 
the literature. To the best of our knowledge, HIF1 has not been shown to be regulated 
by UPR activation. Experiments designed to understand the mechanism by which the 
UPR increases the activity of this factor in regulating VEGF and at least one other HIF 
target, BNIP3 expression when both stresses are applied together revealed an interesting 
finding. We found that these dual conditions appeared to modestly increase HIF1 
binding to the human VEGF promoter, although importantly the experiment was not 
conducted in a way to measure quantitative increases in binding. Interestingly, we did 
observe a modest induction (~2 fold) in the HIF1 transcription rate (hnRNA) with the 
combination of both stresses together, but this was not sufficient to noticeably increase 
VEGF mRNA or protein levels. Thus it is possible that at later time points we would 
begin to see an increase in VEGF transcripts, but within the time frame of our 
experiments, this was not the cause of increased HIF1 binding to the promoter.  On 
preliminary inspection of the HIF1 promoter we were able to identify potential binding 
sites for XBP1(S), ATF4 and NFkB, which are activated downstream of the UPR, but 
further experiments will be needed to determine the significance of this slight increase in 
HIF hnRNA, particularly given the fact that we did not see this increase with UPR 
activation alone . It is possible to speculate that the UPR has the ability to modify the 
chromatin structure of the VEGF promoter at this site, or enhance the transcriptional 
machinery or HIF1 co-factors, like p300/CBP, to facilitate HIF1 binding to the VEGF 
promoter and thus indirectly contributing to VEGF expression. Further studies will be 
required to determine if any of these changes occurs.  Lastly, and perhaps more likely in 
the case when low glucose is used to activate the UPR, it is conceivable that cells become 
hypoxic at an earlier time point, which might result in the stabilization of HIF1 even 
before ATF4 is synthesized.  Although the two sites are not particularly close on the 
linear sequence of the gene, it is possible that the binding of the HIF1 complex to its 
site on the promoter precludes the binding of ATF4 to its site.  The experiments where 
thapsigargin and hypoxia are used together might shed light on this possibility. 
 
From these experiments one thing we can definitely conclude is that the interplay 
between these two pathways in regulating VEGF expression is complex and further 
experiments will be required to determine the exact mechanism of how they synergize 
with one another. Our future experiments will elucidate the importance of ATF4 in 
regulating tumor angiogenesis in orthotopic xenograft studies. 
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Materials and Methods 
 
 
Cell culture and stress induction  
 
SKNASluc and NB1691luc human neuroblastoma cell line stably expressing 
luciferase were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 2 
mM glutamine and 1% antibiotic-antimycotic at 37ºC in a 5% CO2 incubator. Cells were 
plated and left untreated (NT) or treated with thapsigargin (Tg, 1µM), media containing 1 
mM glucose (Low Glu) (RPMI cat. no.11879-GIBCO), or cultured in a hypoxia chamber 
containing 1% O2 for the indicated periods of time. 
 
 
mRNA and hnRNA quantification by qRT-PCR 
  
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the 
manufacturer’s protocol. RNA samples were subjected to reverse transcription using 
High Capacity cDNA synthesis kit from ABI Life technologies. The cDNA was diluted 
and Real-time PCR reactions were done in duplicate using a SyBr Green PCR Master 
Mix kit. Amplification of the corresponding genes was achieved using specific primers 
and measured continuously using an ABI 7900 HTI Detection System. Where indicated, 
VEGF hnRNA was measured using qRT-PCR primers across exon 1 and intron 1, for the 
human gene.  The signal obtained for measuring both, mRNA and hnRNA, was 
compared relative to GAPDH internal control. The value for untreated cells was set to 1 
and the value for the various treatments was presented as a fraction of this number. The 
primers used in this study were as follows: VEGFhnRNA Fwd  
5’GCTGTCTTGGGTGCATTGGAG3’Rev 5’CCATGGACCCGCGTGG5’ 
VEGFmRNA Fwd 5’GTAGCTCGGAGGTCGTGGCGC3’ Rev 
5’GCGAGAACAGCCCAGAAGTTGGACGA3’ 
Gadd34mRNA Fwd 5’GCCAGAAAGGTGCGCTTCTC3’ 
Rev 5’CTCAGCTCCTCCTGGGCC3’ 
BNIP3mRNA Fwd 5’TTAAACACCCGAAGCGCACGG3’ Rev  
5’GACTCCAGTTCTTCATCAAAAGGT3’ 
HIFhnRNA Fwd5’GTGCCCTTTTTAGGTGATTTG3’ Rev 
5’GTGCATTTTACCTGAGTTAATCCC 3'  
 
 
Chromatin immunoprecipitation  
 
Chromatin immunoprecipitation (ChIP) analysis was performed using a ChIP kit 
(Millipore) according to the manufacturer’s instructions. Briefly, cells were incubated for 
the indicated times with or without different stress inducers.  Formaldehyde was then 
added (final concentration, 1%), and cells were incubated for 10 minutes at room 
temperature to stabilize DNA-protein interactions.  Cross-linking was stopped by the 
addition of glycine (final concentration, 0.125M). Cell extracts were sonicated with a 
Branson Sonifier 250 (VWR) for 5 bursts at 10 seconds each at 20% power output to 
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shear DNA to 1kb or less.  Extracts from 107 cells were incubated overnight with 
antibodies against ATF4 generously provided by Dr. David Ron (University of 
Cambridge, U.K.), rabbit anti-XBP-1(S) polyclonal antiserum (Santa Cruz Biotechnology 
sc-7160X), anti-HIF1α (Abcam) or rabbit anti-BiP polyclonal antiserum, which served as 
a negative control. Two percent of the extract volume was removed before 
immunoprecipitation and served as input control. DNA fragments from 
immunoprecipitated complexes and input controls were released by heating at 65ºC 
overnight and purified using the PCR purification kit (QIAquick, Qiagen) according to 
the manufacturer’s protocol. Purified immunoprecipitated DNA and input DNA were 
then analyzed by PCR. The primers used to amplify the regions on the human VEGF 
promoter are as follows: 
“HIF” binding site Fwd 5’GGCTTGGGGAGATTGCTCTACTTCC3’ Rev 
5’GCGAGAACAGCCCAGAAGTTGGACGA3’  
“ATF4” binding site Fwd 5’GGTCGGGCCTCCGAAACCATGAACT3’  
Rev 5’GCAGCGGCAACGCAAGCCCAGC3’  
“XBP-1(S)” binding site Fwd 5’GGTGGGAGCTCTGGGCAGCTGG3’ 
Rev 5’CCAGGGGAGAAGAATTTGGCACCAA3’ 
 
 
Western blotting  
 
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40, and 0.5% deoxycholic acid) for 30 
minutes on ice. The proteins were electrophoresed under reducing conditions, transferred 
to a PVDF membrane and probed with the indicated primary antibodies: Rabbit 
anti-XBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were 
purchased from Santa Cruz Biotechnology and mouse anti-HIF1α from BD Biosciences. 
Blots were incubated with the appropriate HRP-conjugated secondary antibody, and 
proteins were visualized using the Pierce enhanced chemiluminescent substrate (Thermo 
Scientific).    
 
 
Vascular endothelial growth factor ELISA 
 
The quantikine human VEGF ELISA kit (R&D Systems) was used to measure the 
VEGF levels in treated and untreated culture supernatants. VEGF secreted in the media 
was determined based on a standard curve and was expressed in pg/1x106 cells. 
 
 
Generation of dox-inducible ATF4 shRNA in the SKNASluc cell line 
 
Two separate shRNA sequences targeting human ATF4, one specific for the 
3’UTR of the gene and a second sequence that targets exon 4, were cloned into the 
pSuperior-puro vector (Oligoengine), which expresses shRNA molecules from a 
doxycycline-inducible H1 promoter. Both these sequences were validated previously 
using transient siRNA knockdown experiments in the neuroblastoma lines. Two separate 
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vectors; one containing the tetracycline repressor and the other encoding the ATF4 
shRNAs were stably transfected in the SKNASluc cell line. Blasticidin (3g/ml media) 
and Puromycin (1g/ml media) were used to select for clones stably expressing the tet-
repressor and p-Superior vectors respectively. After obtaining antibiotic-resistant double 
transfectants, a number of individual clones were picked using cloning cylinders and 
screened for regulated knock-down of ATF4 expression.  Cells were treated with or 
without doxycycline for 24 or 48 hrs and then treated with thapsigargin for 16 hrs as 
indicated, and the level of ATF4 expression was determined using Western blot analysis. 
The ATF4 shRNA sequence used to clone in the pSuperior vector with BglII and Xho1 
overhangs is as follows: Fwd 
5’GATCCCCCCTTCTGACCACGTTGGATTTCAAGAGAATCCAACGTGGTCAGA
AGGTTTTTA3’ and Rev 
5’TCGATAAAAACCTTCTGACCACGTTGGATTCTCTTGAAATCCAACGTGGTCA
GAAGGGGG3’  
 
 
Lactate assay 
 
The SKNASluc neuroblastoma cell lines were treated as indicated above. Post-
treatment cells were harvested for Western blot analysis and media was collected to 
measure lactate production. Media was deproteinized using a 10 kd spin column 
(Biovision) following which the media was used to determine lactate amounts using a 
Lactate Assay Kit (Biovision). 
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CHAPTER 4.   ROLE OF THE UPR-INDUCIBLE TRANSCRIPTION FACTOR 
ATF4 IN REGULATING ANGIOGENESIS IN VIVO 
 
 
Introduction 
 
After acquiring genetic changes that result in a neoplastic phenotype, highly 
proliferative cancer cells survive in a limiting environment that activates cytoprotective 
stress pathways including the UPR, which has been documented in a number of tumor 
types including breast, hepatocarcinoma, gastric cancer and gliomas in both patient 
samples and xenograft studies.  
 
The three signal transducers of the UPR: Ire1, PERK and ATF6 have reported to 
play roles in regulating tumor angiogenesis in xenograft studies. To elucidate the role of 
Ire1 in regulating tumor growth and angiogenesis in vivo, two separate studies engineered 
U87 human glioma cells with either an Ire1 dominant negative mutant or a control empty 
vector and then orthotopically implanted them in mice [42, 43].  In both studies, tumors 
derived from cells expressing the Ire1-dominant negative mutant were significantly 
smaller, less vascularized but more highly infiltrative as compared to their control 
counterparts.  Cells grown in hypoxic/anoxic conditions in tissue culture and in hypoxic 
areas of the tumor activate a translational control program called the Integrated Stress 
Response (ISR), which adapts cells to endoplasmic reticulum stress. Tumors derived 
from K-ras transformed PERK-/- MEFs were much smaller and had decreased 
microvessel density as compared to the tumors derived from PERK wild-type MEFs 
when injected in the flank of the animals. The decreased angiogenic phenotype observed 
in PERK-/- MEFs was analyzed by microarray and was attributed to down-regulation of 
proangiogenic factor VCIP, an adhesion molecule required for capillary tube formation 
[46]. 
 
Using microarray analysis in a human medulloblastoma line, we found that a 
large number of proangiogenic factors including VEGF were up-regulated by 
thapsigargin. Four proangiogenic factors, VEGF, FGF2, angiogenin and IL8 were further 
analyzed using Real-time PCR. The up-regulation of these factors by ER stress was as 
robust as, or even greater than, that achieved with hypoxia in several different cell lines 
tested.  We found that two UPR-regulated transcription factors, ATF4 and XBP-1(S) 
bound directly to the VEGFA promoter in response to ER stress and contributed to its 
transcription.  In addition, activation of AMP kinase stabilized the VEGFA transcripts, 
further contributing to VEGFA mRNA levels.  At the same time our study was published 
another group reported the importance of the UPR transcription factors, ATF4, XBP-1(S) 
and ATF6 in regulating VEGF mRNA using different knockout MEFs. 
 
An intact UPR is required for various aspects of tumor growth, proliferation and 
angiogenesis. Targeting various components of the UPR is a promising strategy for 
treatment of cancer. A recent study identified STF-083010, a novel small-molecule 
inhibitor of Ire1 endonuclease activity but has no effect on its kinase activity. The 
efficacy of this molecule was tested in a human model of multiple myeloma and was 
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shown to decrease disease burden as compared to untreated controls [124]. Another study 
identified a small molecule, guanabenz that disrupted the stress-induced 
dephosphorylation of the α subunit of the translation initiation factor-eIF2 by direct 
binding to the protein phosphatase 1 PPR15A/Gadd34. Treatment of stressed-cells with 
this inhibitor enabled them to cope with the increased burden of unfolded proteins by 
inhibiting production of new protein and thus restoring proteostasis during stressful 
conditions [125]. Inhibiting critical components of the UPR is a promising strategy as 
treatment options for several disease conditions. To assess the contribution of ATF4 in 
regulating angiogenesis in vivo we will use an inducible knockdown system to inhibit 
expression of this factor in a neuroblastoma tumor model. 
 
Neuroblastoma is the most common solid childhood tumor of the peripheral 
sympathetic nervous system and accounts for 7-10% of all pediatric cancers [126]. The 
tumors arise typically in the adrenal medulla or paraspinal ganglia that can present as 
lesions in the neck, chest, abdomen or pelvis. The clinical presentation of the disease is 
highly variable and can range from a mass that can regress spontaneously, especially in 
infants, to a primary tumor that can locally invade surrounding tissues or a distantly 
disseminated disease observed in children of greater than one year of age. The common 
genetic changes associated with neuroblastoma include N-Myc oncogene amplification 
[127], loss of caspase-8 expression either through gene methylation or deletion [128], 
near triploid karyotype [129] and deletion of short arm of chromosome 1 [130], these 
changes have been correlated with the clinical prognosis of the disease. For example, a 
near-triploidy change in the karyotype of the patient is associated with favorable outcome 
whereas MYCN amplification or allelic loss at chromosome 1p is associated with more 
aggressive tumors and poor prognosis. Studies by different groups have identified three 
discrete sites that are deleted on chromosome 1p36 in neuroblastoma. These regions are 
being mapped intensively to identify putative tumor suppressor genes that are deleted in 
neuroblastoma patients.   Based on the phenotypic and genetic features of the disease, 
neuroblastoma is stratified as low, intermediate and high risk [131]. Low risk tumors are 
localized, can be treated by surgery alone and the survival rate is >98%. Intermediate risk 
neuroblastomas most often occur in infants and are characterized by a localized tumor 
with regional lymph node invasion and metastases to bone marrow and bone. The 
treatment approach is moderate-intensity chemotherapy and surgery that results in a 
90-95% survival rate. High-risk tumors predominantly occur in children older than one 
year of age and are characterized by metastases to bone marrow and bone. These patients 
are treated with intensive multimodal therapy that includes dose-intensive chemotherapy, 
surgery, radiotherapy to primary tumor and resistant metastatic sites, myeloablative 
chemotherapy and immunotherapy. Despite aggressive treatment options, patients older 
than one year and having advanced stage of the disease have a poor survival rate. Only 
40% of neuroblastoma patients that after the age of 4 years survive for 5 years, making it 
necessary to develop more effective and innovative therapy for treatment of malignant 
neuroblastoma.  
 
Neuroblastoma is a highly vascularized solid tumor that depends on the tumor 
vasculature for growth, invasion and metastases. Although the biological mechanisms 
regulating the clinical heterogeneity of neuroblastoma is not completely understood, 
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several recent reports have implicated the importance of using anti-angiogenic therapy as 
a successful treatment strategy for this pediatric cancer. There are three kinds of 
angiogenic inhibitors described: direct, indirect and mixed inhibitors. Direct inhibitors 
like endostatin, angiostatin and thrombospondin target microvascular endothelial cells 
that are required for the proliferation, growth and formation of new blood vessels. 
Indirect inhibitors are agents that are used to block the activity of growth factors like 
VEGF or PDGF that are produced by tumor cells. Lastly, mixed inhibitors are 
multipotent tyrosine kinase inhibitors or interferon-α that affect both tumor cells and 
endothelial cells.  The Food and Drug Administration (FDA) have approved several anti-
angiogenic agents for use in clinical trials including bevacizumab (Avastin), a 
monoclonal antibody that binds to VEGFA and blocks the subsequent activation of its 
receptor signaling [132]. This agent was shown to slow tumor growth and extend the life 
of patients with cancers like colorectal, non-small cell lung cancer and colon cancer. 
Bevacizumab has been used in several xenograft studies to assess its efficacy as treatment 
strategy for neuroblastoma. One study reported that established orthotopic neuroblastoma 
xenografts treated with this drug, altered the physiology of the tumor blood vessels, 
which improved delivery and efficacy of chemotherapeutic agents to the tumor [133]. 
Another study reported that SKNAS, IMR32 and SH-SY5Y xenografts treated with 
bevacizumab were much smaller than their untreated counterparts due to reduced 
angiogenesis [134]. A third study assessed the efficacy of anti-VEGF therapy in 
disseminated disease using the NB1691 cell line. Although they observed a decrease in 
tumor burden and prolonged survival of tumor-bearing mice treated with bevacizumab, 
there was an increase in basic fibroblast growth factor and VEGF expression most likely 
due to inhibition of VEGF signaling [135]. Taken together, these results emphasize that 
VEGF blockade in combination with chemotherapy can be an effective strategy to treat 
neuroblastoma patients.  
 
 Validating our tissue culture results in an animal model is a critical step toward 
delineating the contribution of the UPR-inducible transcription factor ATF4 in mediating 
angiogenesis in vivo and determining whether the UPR might represent a druggable target 
for the treatment of neuroblastoma. Because the PERK pathway, which is responsible for 
ATF4 induction during the UPR, has been shown to be required for growth of K-Ras 
transformed MEFs [46], we have chosen to use a regulated shRNA system for knocking 
down expression of ATF4 in human neuroblastoma cell lines. This will give us the 
flexibility to turn off expression of this factor during various stages of tumor 
development to allow the evaluation of target inhibition on tumor initiation, maintenance 
and metastases.  
 
 
Results 
 
 
Neuroblastoma tumors show evidence of UPR activation 
 
A large number of primary tumor types from St. Jude patients have been adapted 
for xenograft studies and were available for our studies.  However, before choosing a 
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model system for these studies, we wished to identify one that might have relevance to a 
human cancer. Using an affinity purified, anti-CHOP polyclonal antiserum for 
immunohistochemistry staining, we found that multiple pediatric tumor types expressed 
this UPR-induced transcription factor.  We chose neuroblastoma as our model system, 
since a significant number of the pediatric tumor samples were positive for UPR 
activation (Figure 4-1A), there are numerous well-established xenograft lines, and genetic 
mouse models are available. In situ hybridization analyses of tumor sections obtained 
from TH-MYCN hemizygous mice, a transgenic mouse model of neuroblastoma [136], 
revealed up-regulation of BiP mRNA expression, a molecular chaperone that is a UPR 
target, in tumor cells (Figure 4-1B), demonstrating evidence of UPR activation in the 
mouse model similar to that observed in the patient samples. Together, these data provide 
us with evidence that neuroblastoma is a good model system to study the role of UPR 
activation in regulating angiogenesis. 
 
 
Neuroblastoma cell lines induce VEGF secretion on UPR activation 
 
A large number of patient neuroblastoma cell lines have been established at St. 
Jude for use in xenograft studies.  These represent the variety of distinct molecular 
signatures that are observed in patient tumors, including deletion or inactivation of 
caspase-8, a cysteine protease regulated in both a death receptor-dependent and 
independent manner during apoptosis, and/or amplification of the MYCN oncogene [137].  
We obtained 22 different neuroblastoma (NB) cell lines from Dr. Jill Lahti and Dr 
Andrew Davidoff at St. Jude and analyzed them by ELISA for their ability to induce 
VEGF secretion upon UPR activation. The lines were treated with or without 
thapsigargin for 24 hrs and culture supernatants were collected and analyzed. We found 
that VEGF secretion was significantly induced in all cell lines after treatment with 
thapsigargin, however, the fold induction was quite variable (Figure 4-2). Some lines, 
such as NB14 and NB16, have a very high basal level of VEGF secretion, making them 
poor candidates for our studies even though VEGF production was further increased with 
ER stress. Whereas, several others, including SKNAS, NB7 and NB15 lines have a very 
low basal level of VEGF secretion and potently induce VEGF on UPR activation making 
them particularly good candidates for determining the role of the UPR in regulating 
VEGF expression. The VEGF secretion data was further categorized based on two known 
genetic features associated with this cancer (Figure 4-3). Cell lines were first grouped 
into three categories for MYCN protein expression; high, intermediate and low.  We 
observed no correlation in any of the groups for either basal levels of VEGF expression 
or the fold increase in VEGF secretion after UPR activation.  Next, the cell lines were 
subgrouped according to caspase-8 protein expression.  Once again, we found cell lines 
with both high and low basal level of VEGF expression that showed varying levels of 
induction. Thus, UPR-induced VEGF secretion appeared to be independent of both the 
MYCN protein levels and caspase-8 status.   
 
Based on these analyses, we decided to choose lines the SKNASluc and 
NB1691luc cell lines to perform our animal xenograft experiments, as these lines were 
potent inducers of VEGF on UPR activation and both lines have been engineered to  
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Figure 4-1. UPR activation in neuroblastoma tumors. (A) Slides from the tumor 
tissue arrays were stained with rabbit anti-CHOP antiserum.  Portions of two slides are 
shown at low magnification at the left.  A single tumor sample from each slide is 
enlarged.  The top panel is a sample from a ganglioneuroblastoma.  CHOP expression is 
detected in the large ganglian-like cells and in the smaller more poorly differentiated 
neuroblastomas cells that form this tumor. (B) Tumor sections were obtained from a 
genetic mouse model of neuroblastoma (TH-MYCN). The left panel shows Hematoxylin 
and Eosin staining; the darker stained area is the tumor sample with highly proliferative 
cells. The right panel shows expression levels of BiP mRNA by in situ hybridization.  
 
 
 
 
 
 
 
 
 
 
 
A.
B. 
  65
 
 
 
Figure 4-2. UPR activation potently induces VEGF secretion in neuroblastoma cell lines. 22 different Neuroblastoma 
cell lines were either left untreated or treated with thapsigargin, a UPR inducer, for 24 hours.  Media was collected and VEGF 
secretion was measured using ELISA assay. Results are represented as amount of VEGF secreted in pg/ml per 1 million cells.
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Figure 4-3. UPR-induced VEGF secretion in neuroblastoma lines is independent of MYCN amplification and 
caspase-8 protein. Neuroblastoma lines were either left untreated or treated with thapsigargin for 24 hours. Media was 
collected and VEGF secretion was analyzed using ELISA. The NB lines were categorized based on (A) MYCN amplification- 
high, moderate or low and (B) caspase-8- presence or absence.
A. 
B. 
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express luciferase, which makes it possible to do live cell imaging of tumor growth in 
either orthotopic and flank xenograft studies.  In addition, these two lines were selected 
based on their genotype; SKNAS expresses caspase-8 protein, whereas NB1691 does not, 
and the SKNAS cell line has low MYCN protein expression, whereas NB1691 has high 
MYCN expression.  Thus, we have a representative cell line from each of these major 
categories, which should make our studies more clinically relevant.  
 
 
Engineering ATF4 inducible stable knockdown neuroblastoma lines 
 
Since previous studies have shown that full activation of the UPR, including the 
PERK pathway that regulates ATF4 expression, is critical for tumor growth and survival, 
we will use an inducible system to knockdown ATF4 before and after the tumor has been 
established in animal. This design is also critical for determining potential feasibility of 
manipulating the PERK-ATF4 branch of the UPR to treating existing patient tumors. 
Two separate shRNA sequences targeting human ATF4, one specific for the 3’UTR of 
the gene and a second sequence that targets exon 4, were cloned into the pSuperior-puro 
vector (Oligoengine), which expresses shRNA molecules from a doxycycline-inducible 
H1 promoter. Both these sequences were validated previously using transient siRNA 
knockdown experiments in the neuroblastoma lines. Two separate vectors; one 
containing the tetracycline repressor and the other encoding the ATF4 shRNAs were 
stably transfected in the SKNAS cell line. After obtaining antibiotic-resistant double 
transfectants, a number of individual clones were obtained and screened for regulated 
knock-down of ATF4 expression.  Cells were treated without or with doxycycline for 24 
or 48 hrs and then treated with thapsigargin for 16 hours as indicated, and the level of 
ATF4 expression was determined using Western blot analysis (data not shown). Two 
representative clones for a single ATF4shRNA sequence are shown here.  While both 
clones showed robust induction of ATF4 in response to thapsigargin, pretreatment with 
dox for 24 or 48 hour was sufficient to significantly block its expression in response to 
thapsigargin (Figure 4-4A).  These two clones were further analyzed for the effects of 
shRNA expression on the UPR-induced VEGF transcription rate using Real-time PCR 
(Figure 4-4B). VEGF hnRNA levels, an indication of transcription rate, were 
significantly reduced in response to both thapsigargin and low glucose in both of the two 
SKNAS-ATF4 shRNA clones after dox pretreatment as compared to the control lines, 
strongly supporting the role for ATF4 being a major regulator of UPR-induced VEGF 
expression. As a control, Gadd34 up-regulation, a well-characterized ATF4 target, was 
inhibited in the shRNA-expressing lines and induced in the control lines on UPR 
activation (Figure 4-4C). 
 
 
Cell cycle analysis of SKNASluc ATF4 shRNA lines 
 
Before initiating xenograft studies, we wish to determine if the genetic 
manipulations and clonal selection have any gross effects on cell growth.  To determine 
this, we will perform two analyses.  The first was to assess cell growth of these two 
clones before and after dox treatment compared to the control line.  We found that the  
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Figure 4-4. SKNASluc lines with Dox-inducible expression of ATF4- an 
important factor regulating VEGF transcription rate. (A) Western blot analysis of 
SKNAS-ATF4 shRNA clones were either left untreated or treated with Dox for 24hours 
or 48hours. The cells were further treated with thapsigargin for 16hours to induce the 
UPR and ATF4 levels were determined. Real-time PCR analysis of (B) VEGF hnRNA 
and (C) Gadd34, an ATF4 downstream target, was measured in the control and ATF4-
shRNA lines in untreated samples or samples treated with the UPR inducers thapsigargin 
(Tg) or media lacking glucose (Lglu) after 48 hours of pretreatment with dox.   
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two clones expressing ATF4shRNA grew at a similar rate with the control SKNASluc 
cell line in the absence of Doxycycline (Figure 4-5A). In the presence of Doxycycline 
(Figure 4-5B) the control parental line grew slightly faster than the lines having stable 
expression of ATF4shRNA.  We are in the process of cloning the negative control 
shRNA (Renilla luciferase) in the parental SKNASluc line, which will be used in future 
orthotopic xenograft studies. We expect that after obtaining stable Ren luc-shRNA clones 
they would also have the same proliferation rate as our ATF4shRNA clones. We are 
currently analyzing cell cycle distribution of the two clones and the control line before 
and after induction of shRNA expression with dox. 
 
 
Future Experiments/Discussion 
 
 
Orthotopic xenograft experiments to analyze effects on tumor size and 
vascularization after knocking down ATF4 
 
The next critical aspect of characterizing these clones was to insure that both 
would still produce tumors in nude mice.  It was possible that in our genetic 
manipulations, we would have isolated clones that no longer were strongly tumorogenic.  
Alternatively, it was possible that the shRNA would be somewhat leaking even in the 
absence of dox administration and interfere with tumor growth.  To test for these 
possiblities, we performed flank injections in three SCID mice each with either the 
control SKNASluc line or the two clones that inducibly expressed ATF4 shRNA. 
Although in our initial experiment the control line grew up slightly faster, all of the 
clones resulted in tumor growth within 3-4 weeks.  The tumors resulting from the two 
ATF4 shRNA clones were visualized using the Xenogen imaging machine as these lines 
have stable luciferase expression (Figure 4-6). The animals were sacrificed and the 
tumors were either flash frozen or formalin-fixed and paraffin embedded for further 
analysis.  This will include analyzing the tumor sections for UPR target genes like ATF4 
and XBP-1. We will also perform IHC analysis to visualize HIF staining in the tumors. 
 
Now that we have preliminary data showing that the clones expressing inducible 
ATF4 shRNA are able to form well-vascularized tumors in nude mice, we will next 
perform orthotopic xenograft studies, in order to establish tumors from the conditional 
knockdown cell lines in a clinically relevant microenvironment. The dox-inducible 
neuroblastoma cell lines will be injected orthotopically in the retroperitoneal cavity in 
SCID mice. 
 
The animals receiving retroperitoneal injections of the genetically manipulated 
SKNASluc cells will be randomized into 2 main groups, i.e., those with shRNA specific 
for ATF4 and those with shRNA specific for Renilla luciferase as negative control.  Prior 
to knocking down ATF4 expression, we will confirm its presence in tumors that reach a 
size of ~100 mm3 by sacrificing two animals in each group, harvesting the tumor and 
performing western blot analysis to detect ATF4 expression and its downstream targets.  
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Figure 4-5. Cell proliferation rate in the SKNASluc control and ATF4shRNA 
clones. The SKNASluc cell line and two clones with stable expression of ATF4shRNA 
were either (A) untreated or (B) treated with Doxycycline for 2 or 3 days as indicated in 
the figure. Post-treatment the cells were trypsinized and counted. 
 
 
 
 
 
 
 
 
Figure 4-6. Inducible ATF4shRNA clones in the SKNASluc cell line form tumors 
when injected in the flank of SCID mice. SKNASluc cells expressing Dox-inducible 
ATF4shRNA were injected into the flank of SCID mice at 1x107 cells per site. Two 
clones expressing the same shRNA targeting ATF4 were tested with 3 animals per group. 
28 days later tumor growth was visualized by injecting mice with luciferase substrate D-
luciferin and was imaged with a Xenogen CCD camera.  
 
 
  71
Once expression is confirmed, each group will be further divided into 4 subgroups 
(8 animals/group), one group will receive doxycycline 7 days after surgery, as the 
animals need to recover from the invasive procedure. The second group will receive 
doxycycline when tumors reach an average size of at least 100 mm3 and the third group 
will receive doxycycline at a late stage in tumor development when the average size is 
about 250 mm3.  The fourth group will be time-matched animals expressing these two 
clones without receiving any dox.  In the former case, animals will receive doxycycline 
hyclate at a concentration of 25 mg/kg per day by oral gavage, four times a week for the 
duration of the study. This will induce the knockdown of ATF4 in the SKNAS ATF4 
shRNA group but should have no effect on ATF4 expression in the control shRNA 
group.  Time-course experiments with doxycycline will be performed to determine the 
number of days required for administration of the drug to obtain efficient knockdown of 
ATF4 and to assess the optimum time at which tumors will be harvested after 
doxycycline administration. In this way we can determine the short term and long term 
effects of knocking down ATF4 on tumor angiogenesis, as well as to assess 
vascularization in the various tumor samples prior to administering doxycycline. The 
animals in the control group (SKNAS Ren-luc negative control and receiving 
doxycycline) will enable us to assess the effects, if any, doxycycline will have on the 
general health of the animals.  Once the tumors are established, the animals will be 
monitored twice a week using the Xenogen luminometer, to assess tumor size at the 
implantation site. Animals in all groups will be regularly monitored for signs of weight 
loss and neurological symptoms. In our efforts to determine the effects of knocking down 
the UPR-inducible transcription factor, ATF4, on tumor vascularization, we will perform 
a combination of histological, vascular function and phenotype analysis on treated and 
untreated tumors. We will first examine the effect of knocking down ATF4 on 
microvessel density, pericyte coverage and tumor oxygenation status using the methods 
outlined below. In addition to formalin-fixed tissue for in situ hybridization and 
immunohistochemistry analyses, snap frozen tumor samples will be obtained to assess the 
knockdown efficiency in the SKNAS ATF4 shRNA group and determine the extent of 
ATF4 expression in the control groups. 
 
Tumor endothelial cell staining: Formalin fixed, paraffin embedded tumors from 
each group of animals will be obtained. 4µm thick sections will be analyzed by 
immunohistochemistry for CD34, an endothelial cell marker and α-smooth muscle actin 
(αSMA), a pericyte marker, as described previously. Four independent fields will be 
analyzed using a light microscope. Positive staining will be quantified using Image J 
software and will be reported as the mean number of positive pixels/tumor section. In situ 
hybridization will also be performed to analyze mRNA levels of UPR target genes like 
CHOP (an ATF4 target), BiP and ERdj3. We will also analyze activation of the HIF 
pathway by probing for BNIP3 mRNA levels, a downstream target for HIF1 acivity. 
 
RNA and protein analysis: RNA will be extracted from tumors expressing 
ATF4shRNA and Renilla luciferase-shRNA. Real time PCR analysis will be performed 
to determine expression of VEGF. We will also determine expression of other 
proangiogenic factors like FGF2, IL8 and angiogenin. If ATF4 proves to be an important 
regulator of VEGF from our in vitro experiments, then we will check if inhibiting VEGF 
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in vivo has any effect on expression of the other proangiogenic genes important for 
angiogenesis. In addition to analyzing expression levels of the proangiogenic factors, we 
will perform Real-time PCR to determine levels of CHOP, a direct target of ATF4 and 
ERdj3, an off-target control. We expect CHOP expression to be down-regulated in the 
ATF4shRNA tumors as compared to tumors expressing Renilla luciferase shRNA.  
ERdj3 expression levels should be similar in the tumors expressing targeted shRNA and 
negative control shRNA. We will also perform Western blot analyses to determine 
protein expression of ATF4 in knockdown and control tumors. In a similar manner 
described for the in situ hybridization, we will also measure BNIP3 mRNA levels in 
tumor tissue derived from control and ATF4 shRNA samples. Since both pathways, the 
UPR and HIF, are simultaneously activated in tumors we will determine if knocking 
down ATF4 expression has any effect on the HIF pathway. 
 
Tumor oxygenation and intratumoral hypoxia: In a separate group of animals we 
will examine the effects of inhibiting angiogenesis, by knocking down a UPR 
transcription factor, on the oxygenation status of tumors. . We will determine tumor 
oxygenation using a pO2 monitor. This apparatus measures oxygen based on the principle 
of oxygen quenching of fluorescence using a small optical sensor for monitoring rapid 
temporal oxygen changes in a given tissue micro region. We hypothesize that tumors 
expressing ATF4 shRNA may have transient vessel normalization and increased oxygen 
delivery to the tumor compared to control tumors. We would expect to observe a 
transient increase in the pO2 in the ATF4 shRNA tumors as compared to control tumors. 
Finally, to determine intratumoral hypoxia, mice will be injected i.p. with Hypoxyprobe-
1 (Chemicon International) 90 min prior to sacrifice. Tumors will be excised, fixed in 
formalin and embedded in paraffin. Tumor sections will then be stained using the 
Hypoxyprobe-1 Plus kit.  Hypoxia (HIF) positive staining will be quantified using the 
Image J software as described previously. Because tumor hypoxia can be affected by 
tumor volume, size-matched tumors will be used for comparison. In a similar manner 
described above, we anticipate decreased intratumoral hypoxia staining in the ATF4 
shRNA tumors as compared to control tumors.  
 
 
Functional analyses of the tumor vasculature 
 
If experiments described above suggest that knocking down ATF4 in established 
tumors inhibits tumor angiogenesis we will proceed to perform detailed functional 
analyses of the tumor vasculature. 
 
Evans Blue dye assay: VEGF is known to be a potent proangiogenic factor and 
increases vessel permeability. To examine vessel permeability we will inject 100 µl of 2 
% Evan’s dye via tail vein in the ATF4 shRNA and control group that will be allowed to 
circulate for 20 min. Animals will be sacrificed and tumors will be excised and placed in 
formamide for 72 hours to extract the dye. Levels of dye in the extract will be quantified 
(µg/mg) using a spectrophotometer at 620 nm. 
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Contrast Enhanced Ultrasonography: As a measure of functional tumor perfusion 
we will perform contrast enhanced ultrasonography. Briefly, we will inject Optison 
ultrasound contrast agent (Amersham Health, Inc.), which is a suspension of human 
serum albumin microspheres encapsulating octafluoropropane gas. The mean 
microsphere size ranges from 2-4.5 µm and particles remain in the intravascular space. A 
region of interest will be drawn within the ultrasound to encompass the entire tumor, 
which will then be analyzed for precontrast baseline signal intensity, change in signal 
intensity from baseline to initial peak (in dB) and rate of signal intensity increase (in 
dB/s). Using this imaging modality we can evaluate intratumoral perfusion by assessing 
the two variables described above, the change in contrast enhancement and the rate of 
this change. We expect ATF4 shRNA tumors to have improved tumor perfusion and 
consequently these two variables will be much greater than those of the control tumors. 
Finally, we can confirm the functional consequence of the improved tumor perfusion by 
showing a decrease in the intratumoral hypoxia as described above. 
 
 
Materials and Methods 
 
 
Cell culture and stress induction  
 
SKNASluc human neuroblastoma cell line stably expressing luciferase were 
maintained in RPMI 1640 supplemented with 10 % fetal bovine serum, 2 mM glutamine 
and 1 % antibiotic-antimycotic at 37ºC in a 5 % CO2 incubator. Cells were plated and left 
untreated (NT) or treated with thapsigargin (Tg, 1 µM), media containing 1 mM glucose 
(Low Glu) (RPMI cat. no.11879-GIBCO), or cultured in a hypoxia chamber containing 
1% O2 for the indicated periods of time. 
 
 
mRNA and hnRNA quantification by qRT-PCR 
  
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the 
manufacturer’s protocol. RNA samples were subjected to reverse transcription using 
High Capacity cDNA synthesis kit from ABI Life technologies. The cDNA was diluted 
and Real-time PCR reactions were done in duplicate using a SyBr Green PCR Master 
Mix kit. Amplification of the corresponding genes was achieved using specific primers 
and measured continuously using an ABI 7900 HTI Detection System. Where indicated, 
VEGF hnRNA was measured using qRT-PCR primers across intron 1 and exon 2, for the 
human gene.  The signal obtained for measuring both, mRNA and hnRNA, was 
compared relative to GAPDH internal control. The value for untreated cells was set to 1 
and the value for the various treatments was presented as a fraction of this number.  
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Western blotting  
 
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 0.5 % Nonidet P-40, and 0.5 % deoxycholic acid) for 30 
minutes on ice. The proteins were electrophoresed under reducing conditions, transferred 
to a PVDF membrane and probed with the indicated primary antibodies: Rabbit anti-
XBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were purchased 
from Santa Cruz Biotechnology and mouse anti-HIF1α from BD Biosciences. Blots were 
incubated with the appropriate HRP-conjugated secondary antibody, and proteins were 
visualized using the Pierce enhanced chemiluminescent substrate (Thermo Scientific).    
 
 
Vascular endothelial growth factor ELISA 
 
The quantikine human VEGF ELISA kit (R&D Systems) was used to measure the 
VEGF levels in treated and untreated culture supernatants. VEGF secreted in the media 
was determined based on a standard curve and was expressed in pg/1x106 cells. 
 
 
Generation of dox-inducible ATF4 shRNA in the SKNASluc cell line 
 
Two separate shRNA sequences targeting human ATF4, one specific for the 
3’UTR of the gene and a second sequence that targets exon 4, were cloned into the 
pSuperior-puro vector (Oligoengine), which expresses shRNA molecules from a 
doxycycline-inducible H1 promoter. Both these sequences were validated previously 
using transient siRNA knockdown experiments in the neuroblastoma lines. Two separate 
vectors; one containing the tetracycline repressor and the other encoding the ATF4 
shRNAs were stably transfected in the SKNAS cell line. Blasticidin (3 g/ml media) and 
Puromycin (1g/ml media) were used to select for clones stably expressing the tet-
repressor and p-Superior vectors respectively. After obtaining antibiotic-resistant double 
transfectants, a number of individual clones were picked using cloning cylinders and 
screened for regulated knock-down of ATF4 expression.  Cells were treated with or 
without doxycycline for 24 or 48 hrs and then treated with thapsigargin for 16 hrs as 
indicated, and the level of ATF4 expression was determined using Western blot analysis. 
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CHAPTER 5.    DISCUSSION 
 
 
In normal tissues, an appropriate balance between proangiogenic and 
antiangiogenic factors is required to regulate the formation and maintenance of the 
vasculature. A functional network of blood vessels fuels normal tissues and organs with 
nutrients, growth factors, signaling molecules and oxygen. The growth of blood vessels 
or angiogenesis is essential from the early stages of embryonic development, organ 
morphogenesis and throughout adult life. During adulthood, blood vessels are mostly 
quiescent, except in the cycling ovary, during wound healing and in the placenta during 
pregnancy. Its importance has also been implicated in several disease conditions, like 
ischemia, macular degeneration and cancer. Over the past two decades, genetic studies in 
different animal models including mice, zebrafish and tadpoles have provided insights 
into the molecular mechanisms and signaling molecules involved in the regulation and 
growth of new blood vessels. VEGF is the most potent proangiogenic factor required for 
angiogenesis. Other proangiogenic factors like bFGF, and cytokines like IL8 and IL6 also 
contribute to stimulating the development of new blood vessels. Proangiogenic factors 
like PDGF and angiopoeitin-1 play important roles in recruitment of supporting mural 
cells around endothelial tubes. Angiogenesis is a complex process that requires a fine-
tuned balance of several stimulatory and inhibitory signals, chemokines, growth factors, 
oxygen sensors and endogenous inhibitors. The remarkable ability of endothelial cells to 
divide and proliferate in response to physiological stimuli like hypoxia, which leads to 
subsequent activation of the HIF pathway, has been the focus of numerous studies.  In 
addition, recent data from several labs, including ours, have implicated the UPR in the 
production of proangiogenic factors, which suggested that it might also contribute to 
blood vessel formation.  
 
 
UPR Activation Regulates Angiogenesis in Normal Physiological Processes 
 
The UPR is constitutively activated in certain normal tissues and organs like the 
pancreas and muscle that have a high metabolic rate or secrete large amount of proteins. 
It is well established that this cytoprotective response increases ER chaperones, folding 
enzymes and ERAD machinery to enable the ER to cope with increased metabolic 
demands. However, in the past several years increasing evidence obtained primarily from 
experiments with cultured cells, suggests that activation of the UPR might also play an 
important role as a global regulator of angiogenesis by preferentially increasing 
expression of proangiogenic factors and down-regulating antiangiogenic factors [49]. 
Data to support a role in normal angiogenesis came from a recent study where the Ire1 
gene was disrupted.  Ire1 is an up-stream UPR transducer that is conserved from yeast to 
humans and plays a critical role in regulating membrane biosynthesis, molecular 
chaperones, components of the ER degradation machinery, and even cell death [19].  Ire1 
is expressed throughout mouse embryogenesis and adult development.  Studies with an 
Ire1 reporter mouse revealed that Ire1 is constitutively active in the pancreas and muscles 
of adult animals [138], arguing that it contributes to the normal physiology of these 
organs.  Disruption of the Ire1 gene in mice results in embryonic lethality after 12.5 days 
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of gestation [19, 139, 140], demonstrating that it has an essential function early in mouse 
development.  In vivo imaging analysis found that indeed Ire1 is highly activated in the 
placenta of embryos.  More high-resolution studies revealed that loss of Ire1 resulted in a 
severely dysfunctional labyrinth layer of the placenta [139], which is normally highly 
vascularized and is the site of nutrient and oxygen exchange between the mother and 
fetus.  The placenta phenotype in the Ire1 null mice correlated with a significant decrease 
in VEGFA expression in this tissue, which was independent of HIF signaling, as HIF 
protein levels were unchanged between the wild-type and null embryos.  To confirm that 
the early embryonic lethality in the Ire1 null mice was due to inadequate placenta 
vascularization, mice in which the Ire1 gene had been floxed were crossed with Mox2+/Cre 
transgenic mice [139].  Mox2 is ubiquitously expressed in all tissues except in the 
labyrinthine trophoblasts of the placenta, thus allowing Ire1 null embryos to be produced 
that have normal levels of Ire1 in the placenta.  This strategy rescued the embryonic 
lethality observed in the conventional Ire1 null mice and the placentas in the rescued 
mice were well vascularized.  Since the UPR is the only known mechanism for activating 
Ire1, these data argue that the UPR plays a critical role in embryonic development and 
survival by controlling angiogenesis. In addition to the role of the UPR in regulating 
placental angiogenesis, its activation has been detected in highly vascularized normal 
tissues like the human endometrium.  Expression of BiP, the master regulator of the UPR 
is significantly induced in the early proliferative and late secretory phases of the 
menstrual cycle [141].  Although the function of this induction has not been investigated, 
it is reasonable to hypothesize that the UPR also plays a role in the regulation of 
angiogenesis in this tissue.  Although angiogenesis is known to be critical in wound 
healing [142], there are currently no studies to determine if the UPR plays a role in this 
process. 
 
 
Identifying the UPR-Induced Transcription Factor that Up-Regulates VEGFA has 
not been Straightforward 
 
In spite of a number of recent studies implicating the UPR in VEGF regulation, 
identifying the responsible transcription factor(s) has been contradictory. Although the 
mouse genetic studies, strongly implicated Ire1 in regulating VEGF in the placenta, they 
argued that this was not via XBP-1.  Examining placenta in mice that were deficient in 
XBP-1 revealed only mild morphological and histological phenotypes [139].  There was 
no obvious explanation for this finding as XBP-1 has long been considered to be the only 
known target of Ire1’s activity.  Indeed, studies from the Urano lab [121] and ours [49] 
demonstrated direct binding of XBP-1 to the VEGF promoter in humans and mice, which 
results in an increase in VEGF mRNA in human HepG2 and mouse MEFs respectively. 
A separate study injected transformed XBP-1 deficient MEFs into the flacks of SCID 
mice [44].  The resulting tumors were much smaller than the wild-type controls, however 
there was no description of the effects on vascularization.  Cell culture experiments with 
XBP-1 deficient MEFs using extreme hypoxia to activate the UPR showed no difference 
in VEGF secretion compared to wild-type MEFs [44].  This might be interpreted to be 
supportive of the placenta data, however it is critical to note that extreme hypoxia would 
also activate the HIF pathway, which of course would up-regulate HIF.  Two others 
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studies led further support to Ire1 playing a role in regulating VEGFA in a tumor model 
[42, 43].  In both cases a dominant negative construct of Ire1 were expressed in the U87 
human glioma tumor line. Orthotopic studies revealed reduced growth and 
vascularization of tumors, which was linked to decreased VEGFA, as well as other 
proangiogenic factors [42].  From these studies, one might conclude that Ire1, perhaps 
independent of XBP-1, is a major regulator of VEGF. 
 
However, the importance of ATF4 in regulating VEGF expression was suggested 
in cell culture studies by Roybal et. al. using ATF4 null MEFs. Several thiol-containing 
reductive compounds, as well as thapsigargin, were shown to activate the UPR and 
transcriptionally up-regulate VEGF mRNA via an ATF4-dependent mechanism [143].  
However, similar to our studies, the level of VEGF induction with these stresses was very 
modest, which we found was due to a particularly high basal level of transcription in 
these particular cells [49], making it difficult to assess the contribution of ATF4 using 
knockout MEFs. Two other studies supported the role of ATF4 in regulating VEGF 
expression.  In the first case cells were treated with oxidized phospholipids, a common 
lipid component of atheroma that was shown to induce ER stress. They demonstrated 
direct binding of ATF4 to the human VEGF promoter in human HUVEC and HAEC cells 
after treatment with oxidized phospholipids and demonstrated ~50% reduction in VEGF 
mRNA when ATF4 levels were reduced with siRNA [103].  The second study use siRNA 
to reduce ATF4 levels in human HepG2 cells and found a similar reduction in VEGF 
transcripts [121].  These data are in keeping with our studies in two neuroblastoma cell 
lines where we observed an even greater reduction (~ 90%) in the VEGF transcription 
rate and VEGF secretion using siRNA to VEGFA (Chapter 3).  It is unclear if the 
differences in the effects on VEGF are due to variability in the efficiency of ATF4 
depletion or to the cell types used.  Two studies [49, 121], ours included, examined 
whether ATF6 might also contribute to ER stress induced VEGF up-regulation as there 
are putative ATF6 binding sites on the VEGF promoter, but the effects of this 
transcription factor appear to be quite modest.   
  
Thus on face value, it would seem that there are contradictory data to demonstrate 
a significant, and in cases sole, contribution of a single UPR component in regulating 
VEGF transcription; Ire1 and ATF4.  Importantly ATF4 is downstream of the PERK arm 
of the UPR not the Ire1 arm.  Although these branches are thought to signal 
independently of each other it is feasible that there is some interplay between them. For 
example, most recently an XBP-1-independent activity for Ire1 has been identified.  In 
addition to cleaving XBP-1 mRNA, Ire1 was shown to have a rather promiscuous RNase 
activity, known as Regulated Ire1-dependent decay of messenger RNA (RIDD), which 
serves to more globally reduce the expression of RNA transcripts [144].  Although this 
has not been directly examined, it could impact other branches of the UPR.  Alternatively 
it is possible that distinct UPR components or combinations of them are dominant in 
different tissues or cell types.  
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Why should angiogenic factor(s) be a target of the UPR? 
 
A major function of the UPR in cell culture and in vivo, is thought to be restoring 
or maintaining ER homeostasis in response to an inadequate or toxic environment that 
adversely affects this organelle and its ability to fold and assemble proteins. Thus it is 
perhaps not surprising that one mechanism for taking care of this problem in vivo would 
be to increase the supply of blood flow to the affected cells so that more nutrients and 
oxygen can be delivered and waste and other toxic products could be taken away. In 
keeping with this possibility, physiological processes like wound healing require 
increased vascularization, and studies show evidence of UPR activation in the affected 
cells. Although a major focus of my studies and other recent ones was on VEGF, it is 
important to emphasize that our microarray data revealed a 2-fold or greater up-
regulation of 13/19 genes that are positive regulators of angiogenesis.  In addition to 
VEGF, the transcriptional up-regulation of three of these, angiogenin, FGF-2, IL-8 was 
confirmed in a variety of cell lines representing different tissues and species using several 
UPR inducers [49].  The balance in angiogenesis is tightly regulated by both 
proangiogenic and antiangiogenic factors, and interestingly we found that one anti-
angiogenic factor, vasohibin, was down regulated.  Another recent study found several 
other antiangiogenic factors like SPARC, decorin and TIMP-2 to be up-regulated when 
Ire1 activity was inhibited in a human glioma cell line [42]. 
 
However, since inadequate vascularization leads to decreased oxygen in tissues, 
which would induce the HIF pathway, a potent inducer of VEGF, it is reasonable to ask 
why this isn’t sufficient to regulate angiogenesis.  Perhaps the first reason comes from the 
fact that the UPR appears to regulate a multitude of proangiogenic factors, whereas the 
HIF pathway is more focused on VEGF.  Although VEGF is apparently the most potent 
inducer of angiogenesis, in studies where VEGF inhibitors were used therapeutically, 
treatment failure was linked to increased expression of the fibroblast growth factor family 
members [145], which we have shown is a target of the UPR.  Thus the ability to regulate 
so many factors may provide a benefit to the UPR having this capability.  A second 
reason may stem from the stimuli that activate these pathways.  Whereas the HIF 
pathway is uniquely regulated by decreased oxygen availability, the UPR is induced by 
low glucose levels, decreased pH, some heavy metals, and even by extreme hypoxia 
giving it a broader number of potentially toxic conditions to respond to in which 
increased blood flow might benefit the cells.  While all of these conditions have the 
potential to damage the cell, there is another UPR inducer with less toxic characteristics.  
Studies have shown that the UPR can be activated in response to the increased trafficking 
of proteins through the ER.  This can be observed in the secretory tissues, like the 
pancreas, liver and plasma cells, where activation of the UPR increases the capacity of 
these cells to synthesize large quantities of proteins.  This latter inducer of the UPR might 
be particularly important in tissues like the placenta.  The placenta must be highly 
vascularized in order to supply adequate quantities of oxygen and nutrients to the 
developing fetus and to remove toxic waste products. Since HIF1α protein is stabilized 
only in response to limiting levels of oxygen, the ability to vascularize this tissue via the 
HIF pathway would result in intermittent periods of low oxygen in the placenta, which 
could be quite deleterious to the developing fetus.  Indeed, the highly vascularized 
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placenta does not have any detectable levels of HIF1α protein but instead shows strong 
evidence of UPR activation.  This suggests that the cues to activate angiogenesis in this 
tissue might be less dependent on an inadequate microenvironment but instead rely on the 
high secretory nature of the placenta. This raises an important point of how normal 
physiological processes like angiogenesis can be controlled by alternate compensatory 
pathways in different organs or cell types. This aspect of the UPR in regulating 
angiogenesis in a HIF-independent manner might also be used in pathological conditions 
like cancer, and ischemia to stimulate angiogenesis, as in both cases there is evidence of 
UPR activation. 
 
 
Does the UPR contribute to angiogenesis in tumor cells that also activate HIF? 
 
In contrast to normal differentiated cells that rely on mitochondrial oxidative 
phosphorylation to produce energy for most cellular processes, cancer cells rely on 
glycolysis, a phenomenon known as the “Warburg effect”. The reason for cancer cells to 
shift to a more inefficient method for producing energy is still under investigation but 
some studies suggest that this facilitates the production of nucleotides and other 
metabolic intermediates that are conducive to cell proliferation. A hypoxic environment 
stabilizes HIF, which significantly contributes to the conversion of glucose to lactate, the 
end product of glycolysis. Adaptation to the tumor microenvironment results in increased 
glucose uptake and lactate production. However, the tumor microenvironment often 
encounters decreased nutrients and glucose supply in addition to hypoxia. Thus, it is 
important to assess the contribution of other pathways like the UPR to tumor cell 
metabolism. 
 
Studies are required to determine the percent of cells in a tumor that activate the 
UPR and HIF signaling pathways alone and the percent that activate both pathways 
simultaneously. Our studies show that activation of both pathways together are potent 
inducers of VEGF expression compared to when each pathway is activated alone. Thus 
identifying the expression profile of these pathways in tumors will be important. The 
mechanism of how these two pathways influence each other to potently induce VEGF 
expression is still unknown. It is possible that the UPR could enhance the activity of HIF 
by yet unknown post-transcriptional mechanisms. The UPR could also have the ability to 
enhance binding of HIF to its target genes like VEGF, by modifying the chromatin 
structure and making it more accessible for HIF transcriptional machinery to bind and 
transactivate its target genes. 
 
Studies from our lab show that the UPR is activated throughout the tumor tissue, 
this is largely due to the rapid proliferation and high metabolic rate of tumor cells. Thus, 
areas that do not have the HIF pathway activated could still have the UPR activated with 
subsequent activation of downstream transcription factors like ATF4. We would thus 
expect ATF4 to be a critical regulator of VEGF expression in most parts of the tumor. 
The follow up studies for this project in the orthotopic neuroblastoma tumor model will 
enable us to determine the contribution of the UPR-inducible transcription factor ATF4 in 
regulating tumor angiogenesis during different stages of tumor growth. The 
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Dox-inducible regulation of ATF4 will give us the flexibility to turn off its expression 
during early and late stages of tumor development. In this way we can determine the 
relative importance of the UPR and HIF signaling in regulating tumor angiogenesis and 
thus identify a druggable target for inhibiting angiogenesis. 
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APPENDIX.   SUPPLEMENTAL FIGURES FOR CHAPTER 2 
 
 
 
 
 
Figure A-1. HIF signaling pathways are not activated by UPR inducers nor are 
UPR targets activated by hypoxia.  C6 cells were treated with 100 µM CoCl2, 1% O2 
hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media 
(No Glu) for 24 hours. Western blot analysis was performed to measure (A) BNIP3 and 
CHOP protein levels in the cytosolic fraction. Hsc70 was used as a loading control. (B) 
HIF1α levels were determined in the nuclear fraction using Lamin B1 as control and 
CHOP levels were determined in the cytosolic fraction using Hsc70 as control. 
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Figure A-2. UPR inducing agents up-regulate CHOP and BiP mRNA. Daoy, C6, 
NB1691, SKNAS and NIH3T3 cells were treated with 100 µM CoCl2, 1% O2 hypoxia 
(Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media (No 
Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and expression levels of 
CHOP mRNA (black bars) and BiP mRNA (white bars) were determined relative to 
18SrRNA. Experiments were performed in triplicate (values are mean ± SD).  
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Figure A-3. Basal levels of proangiogenic factor expression in different cell lines. 
Daoy, NB1691, SKNAS, C6 and NIH3T3 cells were treated with 100 µM CoCl2, 1% O2 
hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media 
(No Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and basal levels of 
expression for (A) VEGF (B) angiogenin (C) FGF2 and (D) IL-8 were determined 
relative to 18SrRNA. Experiments were performed in triplicate (values are mean ± SD).  
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Figure A-4. Potential binding sites of UPR downstream transcription factors in 
human, mouse and rat VEGF promoter. Two online softwares, rVista and 
TRANSFAC were used to screen potential binding sequences of transcription factors, 
XBP-1 (cyan), ATF4 (green), HIF (red) and ATF6 (yellow) in 9k upstream promoter 
region of human, mouse and rat VEGF gene.  
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Figure A-5. Basal levels of VEGF hnRNA in XBP-1 wild-type and null MEFs. 
XBP-1 wild-type MEFs (black) and null MEFs (white) were untreated (NT), 
Thapsigargin-treated (1µM), treated with media lacking glucose (No Glu) or 
Homocysteine-treated (HCys, 10mM) for 8h and 14h. Total RNA from the indicated 
samples was subjected to qRT-PCR and VEGF hnRNA/18S ratios were determined 
relative to the control untreated samples.  
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Figure A-6. ATF4 does not appear to bind to the rat VEGF promoter. (A) 
Potential ATF4 sites in the rat VEGF promoter. (B) Cross-linked chromatin from C6 cells 
that were untreated (NT), Thapsigargin-treated (Tg), or incubated in No glucose media 
(No Glu) for 8h were immunoprecipitated with anti-ATF4. As positive control, primers 
spanning the ATF4 binding region on the CHOP promoter were used to PCR amplify the 
anti-ATF4 precipitated chromatin (C) CHOP protein levels were determined using 
Western blot analysis in the C6 cells that were used in the ChIP assays.  
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